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The expression of recombinant proteins often exploits amino acid motifs that can 
provide unique properties for recognition, post-translational modification, binding 
capacity, and translocation potential.  Implementing a poly-histidine tag, for example, 
creates a unique binding site for efficient purification of a target protein from 
unwanted impurities.    This tag can later be cleaved rendering the functional ‘native’ 
protein.  Inteins are natural, “protein ligators”, facilitating the formation of a covalent 
bond between two flanking protein fragments (exteins) of a translated protein 
sequence.  The intein excises itself upon ligation of the flanking exteins.  Split-inteins 
can flank a target protein and upon an excision event, they enable a post-translational 
mechanism that cyclizes the protein by cleaving out the flanking intein sequences. 




macromolecules across the cell membrane, while maintaining membrane integrity.  
Nucleic acids, proteins, and small molecules can be linked to the CPPs through a 
covalent bond or a non-covalent interaction to facilitate their translocation into the 
cell.  The uptake of a CPP-protein fusion is typically rapid and follows first-order 
transduction kinetics.   
CPP-mediated uptake can be rapidly measured by quenching extracellular 
fluorescence with trypan blue.  Trypan blue will penetrate cells with compromised 
membranes that could transduce proteins unmediated. In this study, eGFP is 
expressed alongside the transactivator of transcription (TAT) peptide derived from 
HIV-1 that can function as a cell-penetrating peptide. The TATeGFP fusion protein is 
also expressed alongside an artificial split-intein system.  The cyclized TATeGFP 
protein exhibits enhanced in vitro stability during protein expression, resistance 
against exopeptidase digestion, and resistance against chaotropic agent degradation.  
A cell-penetrating peptide-protein fusion can transduce a cell membrane to deliver an 
intracellular protein with low cytotoxic effects.  A cyclical, cell-penetrating, peptide-
protein fusion is a novel tool for fluorometric reporting studies and a backbone for the 
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Chapter 1: Introduction and Literature Review 
1.1 Problem Description and Motivation 
 
 Therapeutic proteins have revolutionized modern health care.  The immense 
potential to influence diagnostic studies and therapeutic care are limitless.  Proteins 
catalyze in vitro and in vivo diagnostic studies to advance the treatment for diseases 
and conditions.  Maintaining function while retaining stability is a primary challenge 
for early drug development studies.  Proteins are susceptible to degradation—from 
enzymatic digestion to unfolding by thermal and chemical inducers.  Monitoring 
protein degradation requires a short-time scale and utilizing fluorometric reporters 
offer a real-time, on-line platform for rapid measurement and analysis.  
 Exogenous proteins primary interaction with cells exists only in the outer 
membrane.  The cell membrane an effective barrier of the inner membrane and 
strictly regulates the transduction of foreign molecules.  Exogenous protein 
transduction can be facilitated by small peptides, penetrating the outer membrane 
while retaining the native state of the protein.  A fluorometric reporter system, 
capable of cell transduction, engineered with enhanced stability, is a unique platform 
for therapeutic protein research.   This chapter reviews a broad framework of 
scientific theory and published results that support the experimental method of this 






1.2 Literature Review 
 
1.2.1 Recombinant Protein Expression in E. coli 
 
E. coli is the most prevalent host organism for recombinant protein expression.  The 
highly-characterized organism is widely used for the study of protein transcription, 
translation, and protein folding.  It is an attractive substrate for research platforms based 
on its rapid doubling time, inexpensive growth media, well-characterized genetics, and 
the ease to culture at high-cell densities [1].   
For protein expression in E. coli, heterologous DNA are introduced through a 
recombinant plasmid.  The target DNA sequence is introduced into the plasmid by 
flanking the sequence with restriction enzymes that allow for complimentary sticky 
ends to facilitate recombination.  The DNA sequence can also be introduced through 
amplifying oligomer sequences through a polymerase chain reaction (PCR) [2].  The 
recombinant plasmid often is encoded with an antibiotic-resistance marker.  When the 
growth media is supplemented with the specific antibiotic, plasmid-free cells either die 
or fail to propagate.  Antibiotic resistance genes do cause limitations for expression and 
target applications.  The selective pressure applied by the antibiotic resistance gene will 
be reduced or eliminated from the degradation or inactivation of soluble antibiotics [3].  
Moreover, the desired recombinant protein could become contaminated with the 
soluble antibiotic.  The Food and Drug Administration (FDA) places strict regulations 
on the usage and acceptable concentrations of antibiotics for protein expression [3-5].   
Control of the protein expression can be modulated by utilizing a repressor-protein 
gene on the recombinant plasmid.  The repressor-protein gene, or promoter, is inserted 




protein, the promoter is not transcribed when the DNA-binding protein is present.  
Small molecules can induce the release of the DNA-binding protein allowing for 
transcription from the promoter and into the target DNA sequence to proceed.  The 
most prevalent promoter system in E. coli is the bacteriophage T7 late promoter.  
Protein expression is controlled by the T7 RNA polymerase binding  to the lacUV5 
promoter [6].  Under normal conditions, the lac operon is upstream of the target DNA 
sequence on the recombinant plasmid.  The transcription of the lac operon (and thus 
the target DNA sequence) are inhibited as the lac repressor binds to the lac operon 
DNA sequence [7].  The lac repressor is a DNA-binding protein that, when bound to 
the lac operon, enhances the affinity of the RNA polymerase for the promoter sequence.  
This prevents the RNA polymerase in continuing transcription along the plasmid.  This 
mechanism is functional when lactose is not present in the cell media.  When present, 
lactose is metabolized into allolactose, inhibiting the binding ability of the lac repressor 
[7-10].  IPTG can mimic the function of allolactose and is widely use to induce protein 
expression of heterologous proteins in E. coli [11-13]. 
 The recombinant plasmid can encode DNA sequences for genes that encode 
proteins that can help facilitate and enhance protein expression, purification, and 
analysis.  The additional genes encode a fusion protein that is non-inhibitory on the 
target protein structure and function.  Small poly-peptide sequences can enhance the 
selectivity of the target protein for affinity chromatography media.  The poly-histidine 
sequence (six, repeated histidine residues) has a strong affinity for immobilized metal 
affinity resins.  This 6-His sequence can be introduced at the 5’ or 3’ end of the target 




visualization and analysis of protein expression level and relative location: expression 
in the periplasm, cytoplasm, or secreted into the culture media [16].  A FLAG-tag 
(amino acid sequence, DYKDDDDK) can be introduced as a fusion protein to facilitate 
immunoprecipitation of the target protein.  If the target protein does not have a well-
characterized monoclonal antibody, a FLAG-tag can allow for highly-specific 
immunochemistry reactions for protein analysis studies [17, 18]. 
 Fermentation conditions are optimized for highly-expressing recombinant 
protein E.coli clones.  The fermentation is initiated when a single colony is inoculated 
into a growth media containing the selective-pressure antibiotic coded into the plasmid.  
This small volume culture is cultured using high agitation (>200 RPM) and at optimal 
growth temperature, 37.0°C.  Upon reaching the mid-logarithmic phase, the culture is 
used to inoculate a larger volume of culture media to be used for protein expression.  
The inoculum restarts the growth phase to the lag phase or early-logarithmic phase [19, 
20].  Induction of protein expression using IPTG is often initiated during the mid-
logarithmic phase.  The culture media still has sufficient nutrients to supply the cells 
during the induction phase [16].  Often, the induction phase is operated at a lower 
temperature.  The lower temperature reduces the effect of proteolysis, and often 
facilitates better protein folding and the inhibition of formation of inclusion bodies.  
Inclusion bodies, although enhance the purification efficiency of the protein, are often 
expensive and unsuccessful in re-folding the target protein [21-23].   After the induction 
phase, the expressed protein is harvested by centrifugation. The E. coli cells are 
separated from the culture media in a cell pellet.  The cells can be mechanically, 




protein can be purified using filtration or chromatography.  Chromatography can 
exploit the fusion proteins for the rapid purification of the protein [16] 
E. coli strain DH5-α was designed for the efficient amplification of plasmid 
DNA.  The wild-type K-12 had several genetic modifications, either deletion, mutation, 
or introduction.  The strain has been designed for high transformation efficiency, 
plasmid stability, and recombination efficiency [25, 26].   E. coli has endonucleases in 
the periplasm that efficiently digest exogenous DNA. The mutation of the endA1 gene 
enhances plasmid transfer rates by decreasing endonuclease degradation.  [27].  
Traditional cloning utilizes antibiotic resistant genes on backbone plasmids and sticky 
or blunt ends of nucleotide sequences for ligation.  The mutation of the recA1 gene 
reduces the efficiency of homologous recombination [25, 26].   The DH5-α strain is 
commonly used during plasmid construction, modification, and amplification.   
E. coli strain BL21 derivatives were designed for efficient recombinant protein 
production.  E.coli strains contain genes that express proteases that digest heterologous 
proteins [28].   The BL21 strain has deficient genes responsible for expression of outer 
membrane protease and cytoplasmic protease [29, 30]. The λDE3 lysogen contains a 
gene that expresses T7 RNA polymerase.  This polymerase is induced using IPTG 
which facilitates the expression of proteins downstream of the T7 promoter [31, 32].  
Rosetta BL21(DE3) is a strain from Thermo (Carlsbad, CA) that is traditionally used 
for recombinant expression of heterologous proteins.  It also has the unique ability to 
express proteins with codons not traditionally used in E. coli.  Recombinant plasmids 




1.2.2 Fluorescent Proteins 
 
Luminescence is the emission of light.  An electronically excited state from any 
substance can emit luminescence.  Luminescence, existing in two forms, fluorescence 
and phosphorescence, has become an important tool for life science applications.  
Phosphorescence is emitted when an electron in an excited orbital is paired with an 
electron of a ground state orbital of similar spin.  Fluorescence is emitted with an 
electron in an excited orbital is paired with an electron of a ground state orbital of 
opposite spin.  Relatively, fluorescence emission (10-8 seconds) occurs at a much 
more rapid rate than phosphorescence (100-103 seconds).  Therefore, a fluorophore 
has a lifetime of 10s whereas a phosphor has a lifetime of seconds to minutes [33].  
Fluorophore’s have a distinct advantage in that many kinetic reactions occur on the 
same order of a fluorophore lifetime allowing for the distinct measurement using 
sensitive instruments. 
When a fluorophore absorbs light, two specific processes occur: excitation into a 
higher energy orbital, followed by the return to thermal equilibrium and emission of 
fluorescent light.  The excitation of the fluorophore occurs relatively rapidly, on the 
order of 10-12 second or less, to a higher vibrational state.  Since this occurs rapidly, it 
does not alter the nuclear geometry.  When the fluorophore returns to its ground state 
and produces an emission spectrum, and the transition occurs at a relatively slower 
rate, on the order of 10-8 seconds.  The fluorescence emission typically occurs at 
lower energy and longer wavelengths than the excitation, observed as the Stokes Shift 




The Stokes Shift that occurs between the excited state and the emission state occurs 
due to decay of the fluorophore’s ground energy state, solvent-dependent energy 
transfer, or changes in the molecular structure during excitation [36].     
Fluorescent proteins can be defined by their excitation and emission 
wavelengths or their fluorescence lifetime and quantum yields.  The brightest 
emitting fluorescent proteins emit the highest number of photos relative to the number 
absorbed.  This ratio, the quantum yield, can be calculated using two rate constants: 
the emissive rate of the fluorophore and the rate at which the fluorophore decays [37, 
38].  The same rate constants can be used to calculate the lifetime of the excited state 
of the fluorophore.  The fluorescence lifetime of a fluorophore is measured by the 
duration of the excited state. 
A fluorescent protein’s intrinsic ability to produce an emission spectrum can be 
quenched.  Removed by molecular interactions or trivial mechanisms, the quenching 
of fluorescent proteins is a useful tool in biochemical applications.  The interaction of 
the excited fluorophore with an exogenous molecule often interrupts the process of 
returning to its ground state and emitting a fluorescent wavelength.  Moreover, this 
interaction could cause a molecular change in the fluorophore preventing the 
excitation phase completely.  Trivial and non-molecular mechanisms, such as buffers 
or masking agents that absorb emission [39-41]. 
Fluorophore’s have been widely used as research tools in biotechnology, drug 
discovery, medical diagnostics, and forensics.  Cellular mechanisms, binding kinetics, 
and protein folding can be detected using fluorescent proteins.  The most widely 




naturally in the jellyfish Aequorea Victoria as a major excitation peak at 395nm and a 
major emission peak at 509nm.  GFP is widely used as a gene expression reporter and 
an easily detectible marker for extracellular and intracellular protein dynamics [42].  
In 1961, O. Shimomura began catching jellyfish in nets and mechanically separating 
the jellyfish’s umbrella.  After isolating the bioluminescent Aequorin, a calcium-
activated fluorophore, Tsien, observed an additional fluorophore, GFP [43, 44].  D.C. 
Prasher published the nucleotide sequence and the results of the molecular cloning of 
GFP in 1992, but could not express heterologous GFP that emits fluorescence [43, 
45].   M. Chalfie received the non-fluorescent clone from Prasher and identified an 
inhibitory sequence at the C-terminal end of the cDNA.  Removal of the inhibitory 
sequence created the promoter-controlled expression of GFP in C.elegans [43, 46]. R. 
Y. Tsien also obtained the clone from Prasher and performed the early development 
studies of the structure-function of GFP.  Through random mutagenesis, and 
mutations identified from biophysical studies, Tsien created several GFP variants 
with enhanced fluorescence, as well as fluorescent proteins that emit yellow, cyan, 
and blue fluorescence [43, 47, 48].   
GFP has been extensively utilized for studying recombinant protein expression 
and production.  GFP remains a stable biomarker for intracellular fluorescence and 
protein identification [49].  The tertiary structure of GFP permits functional 
bioactivity of the fluorophore when expressed alongside a macromolecule.  The N- 
and C-termini of GFP are distant from the fluorophore-inducing beta-barrel structure, 
creating an efficient linker to a fusion partner.  When expressed alongside the fusion 




GFP can be expressed alongside a target protein for the rapid detection and 
measurement of intra and intermolecular processes.  For proteins that transport 
molecules through and outside of the cell, GFP can be used a fusion partner for the 
localization of the movement.   Four color variants of fluorescent proteins can report 
the distinct four phases of the cell growth cycle: G1, S1, G2, and M.  The cells, Fucci 
modified cells, can report yellow, green, and red during the latter three cell growth 
phases [51].  GFP has been fused to reporter and transport proteins to aid the study of 
how molecules move through cells [52], monitor heterologous expression in real-time 
[53], and quantitate amplification of recombinant baculovirus particles [54].    
 The recombinant expression of GFP must undergo a series of first-order 
modifications to emit fluorescence.  This first-order reaction is rate-limited by oxygen 
concentration and wild-type GFP in A. Victoria requires 3.5h for maturation of the 
fluorescent signal after protein synthesis.  When expressed on a recombinant plasmid, 
GFP persists intracellularly even after promoter activity has been halted [46, 55-57].   
1.2.3 Inteins 
 
Inteins function as protein ligation catalysts, facilitating the splicing of two 
translated peptide sequences into a functional protein.  Over 35 different organisms 
have an intein-based ligation system integrated into their DNA, originating primarily 
from the Bacteria and Archaea family.   These inteins can function as DNA and RNA 
polymerases, proteases, and enzymes [58].  Intein splicing requires three key 
components: An N-terminal fragment (N-extein), the intein, and a C-terminal 
fragment (C-extein).  The entire process stems from translation of a single 




the target of interest is split into a N-extein and a C-extein that flank the functional 
intein. Based on thermodynamic stability from the N and C-terminal amino acid of 
the functional intein, the intein excises from the translated protein sequence.  The 
excising of the intein forms a covalent bond between the extein fragments, creating a 
functional protein [59-65].  The nonspecific excised intein is discarded.  The overall 
efficiency of intein expression and splicing is reduced as homing endonucleases are 
present in the full sequence [66].   Intein-based protein expression has been leveraged 
to enhance and streamline protein purification, post-translational modifications, and 
mini-intein structures that eliminate the homing endonuclease domain and facility 
cyclic protein expression. 
Inteins are considered as “selfish” proteins.  Genes present in single-celled 
bacteria and archaea containing inteins have been replaced with a non-intein based 
protein from a related organism with no difference in gene function [67].  Since the 
inteins are integrated in highly-conserved regions, it would be difficult for natural 
selection to delete and thus face extinction.  It has been hypothesized that inteins 
enhance the selectivity, function, and possibility of deletion for highly-conserved 
protein motifs [68].  Moreover, if an intein in a highly-conserved region is not 
expressed, it has been shown the overall function and fitness of the host protein is 
modulated.   Thus, protein expression could be modulated by inteins responding to 
their environment: pH, buffer, or thiol concentration [69-71].  This phenomenon has 
been observed in principal in nature, but not demonstrated.  The cyanobacteria, 
Synechocystis, has the intein domain split in halves.  The N-extein is located on the 




DnaeE intein functions as a post-translational modification in vitro.  The specific 
activity of the intein for host protein control has not been demonstrated in its native 











Figure 1. Three mechanism of intein ligation: traditional inteins, split-inteins, 
and cyclized split-inteins.  The traditional intein mechanism is a single translated 
protein that results in the intein flanked by an N-terminal extein and a C-terminal 
extein.  Upon ligation, the two extein fragments form a covalent bond and release the 
intein [source].  The split intein mechanism is initiated with two independently 
translated protein sequences.  The intein fragment from the traditional intein 
mechanism was expressed in two parts.  The first half was expressed on the C-
terminal end of the N-extein, and the second half was expressed on the N-terminal 
side of the C-extein.  The two halves of the intein form a covalent bond and the 
traditional intein mechanism proceeds.  The cyclized split-intein mechanism is a 
single translated sequence.  The intein halves from the split-intein mechanism are 
expressed as flanking regions to a target protein.  The N-terminal half is expressed on 
the C-terminal side whereas the C-terminal half is expressed on the N-terminal side.  
Upon the completion of the processing, the target protein is excised as a cyclized 






1.2.3.1 Cyclic peptide synthesis using inteins 
 
 
The modified intein based splicing mechanism, found in Synechocystis, 
expresses the initial translated protein sequence into two independent motifs: an N-
terminal fragment containing the N-extein and half of the Intein, and a C-terminal 
fragment containing the C-extein and the remaining half of the Intein (Ssp DnaE). In 
this case, the two sequences are translated from two independent expression vectors, 
and purified separately.  The reaction takes place from two purified, translated 
sequences.  In Figure 1B, there are two ligation reactions in this mechanism: first the 
intein ligates itself forming an active intein-extein complex, then undergoes the 
similar intein splicing mechanism of Figure 1A producing a ligated protein and an 
excised intein [71, 74, 75]—Frame B of Figure 1.  Finally, in Figure 1C, the split-
intein based system developed by Benkovic and coworkers [76-79], creates a 
circularized target protein—SICLOPPS Intein.  
	
Figure 2. The Key amino acids of the translated cyclized, split-intein mechanism 
(SICLOPPS).  The C-terminal amino acid (IC36) of the C-intein is Asparagine, the 
N-terminal amino acid of the target protein is a cystine or serine (TP01), and the N-
terminal 
		
In this mechanism, the target protein is translated between the functional 
intein that has been split into two parts.  The N-terminal intein fragment has been 
translocated to the C-terminus and the C-terminal intein fragment translocated to the 




amino acids that flank the intein in Figure 1A have been inverted.  In Frame C of 
Figure 1, the translated sequence has three segments: a N-terminal intein fragment 
(Cintein), the target protein, and a C-terminal intein fragment (Nintein.)  The target 
protein is excised from the two-intein fragments as a circularized protein.  The two 






Figure 3. Split-intein based cyclization of a target protein (SICLOPPS).  The four 
major steps that occur during a split-intein derived cyclization (SICLOPPS) of a 
target protein are: acyl shift, transesterification, asparagine cyclization, and an acyl 
shift.  The key amino acids (Figure 2) that drive the process are the N-terminal amino 
acid of the InteinC (Asparagine—IC36), the N-terminal amino acid of the target 







1. Acyl shift of the Nintein to form a Thioester: The HS side chain of the N-
terminal amino acid of the Nintein (Cystine) exercises a nucleophilic attack on 
the C-terminal carboxy group of the target protein.  The leaving group (NH) 
from the N-terminal amino acid of the Nintein is cleaved.  The IC-Target 
Protein-IN motif is maintained. 
2. Transesterification of Target Protein and Nintein to form a Lariat: The XH side 
chain of the N-terminal amino acid of the target protein (Cystine/Serine) 
exercises a nucleophilic attack on the C-terminal carboxy group of the target 
protein.  The leaving group (SH) from the N-terminal amino acid of the Nintein 
is cleaved.  This cleaves the Nintein from the IC-Target Protein-IN motif [73].    
3. Cintein Asparagine cyclization fragment releases a Lactone: The C-terminal 
residue of the  Cintein fragment is asparagine.  The amine group of the 
asparagine exercises a  nucelophilic attack on the N-terminal carboxyl group 
of the asparagine.  This cleaves the Cintein from the target protein forming a 
lactone (a circular target protein) [80].  
4. Acyl shift in the lactone to form a functional cyclic target protein: The H2N 
side chain of the of the target protein (Lactone) exercises a nucleophilic 
attack on the C-terminal carboxy group of the target protein.  The leaving 







1.2.3.2 Cyclic peptides as therapeutic models 
 
Cyclic peptides offer a promising template for therapeutic models.  Having shown 
enhanced thermodynamic stability, and function, utilization of a cyclic peptide has 
shown promising clinical data.  Anti-bacteria peptides have been cyclized: gramicidin 
has been chemically synthesized and expressed alongside the Ssp DnaE split-inteins 
[82], tyrocidine has been chemically synthesized and expressed alongside the Nostoc 
punctiforme PCC73102 (Npu) DnaE split inteins[83, 84], and cyclosprorin A has 
been expressed alongside both the Npu and Ssp split-inteins [84, 85]. 
1.2.4 Cell Penetrating Peptides 
 
The outer membrane of a cell controls the transport of material inside the cell.  
Small molecules—salts, sugars, and amino acids, are transported by membrane 
channels and signaling proteins.  Larger molecules—proteins, nucleic acids, and other 
large molecules, are transported by endocytosis or exocytosis.  The outer membrane 
contains a fluid, phospholipid bilayer, stabilized by a polar outer surface of and a 
nonpolar interior.  Hydrophobic proteins that prohibits the passage of peptides, 
proteins, nucleic acids, and other foreign substances from entering the cell.  The 
selectivity of the outer membrane complicates the manner for which therapeutic or 
diagnostic macromolecules can penetrate the cell membrane. To combat the 
hydrophobic nature of the cell membrane, physical mechanisms have been used to 
deliver cargo: microinjection and electroporation.  These mechanical methods often 
induce stress to the cell resulting in programmed cell death or changes in cell 
physiology.  To prevent the mechanical stress that would be imposed by using a 




based vectors.  In 1988, the HIV TAT transactivating factor was discovered and 
determined it could translocate across the cell membrane.  This protein, 86 to 101 
amino acids in length depending on the sub-type, has a short 11-amino acid motif that 
encodes the translocation factor of the protein [86].    Since the discovery, numerous 
natural and synthetic cell-penetrating peptides (CPPs) have been studied to facilitate 
the transfer of macromolecules inside the cell in a low cytotoxic and non-mechanical 
transduction pathway. Since its discovery, the TAT peptide has shown low 
cytotoxicity, low cell-specificity, and dose-dependent cell translocation efficiency 
with minimal restrictions of the type and size of the delivery cargo. 
 
1.2.4.1 Cell Transduction Methods and Thermodynamics 
 
Macromolecules can cross the plasma membrane of cells through energy-
dependent or energy-independent transport.  One method of energy-dependent 
transport of proteins, nucleic acids, or macromolecules is endocytosis [87, 88].  
Energy is required to create a surface vesicle after the hydrophilic polypeptide or 
oligonucleotide has adsorbed to the plasma membrane proteins [89].  Inside the 
vesicle, the macromolecule is tagged for digestion, degradation, or release into the 
cytoplasm.  Energy-independent transfer across the membrane is not receptor-
specific, nor does the hydrophilic molecule adsorb to a membrane protein [90, 91].  
This method of macromolecule transduction, direct penetration, leads to the non-cell 
specific nature of many cell-penetrating peptides [92]. 
Cell-penetrating peptides are utilized to deliver macromolecules to cells primarily 




non-covalently linked as a “cargo” to a short peptide sequence that is non-selective 
and passive in targeting a delivering the cargo to cells [93, 94].  The cargo can be 
modified to increase selectivity to a specific class of cells to enhance cell 
transduction, mediate gene expression, or modulate protein expression and function.   
The exact mechanism of CPP transduction has not been confirmed through 
multiple studies.  It is likely that CPPs without cargo can transduce the cell through 
multiple pathways: direct penetration of the cell membrane or endocytosis [95-97].  
When CPPs are coupled to cargo used to detect these pathways, there have been 
contradictory results claimed—most likely due to the experimental nature of the 
pathway study.    The cellular uptake and transduction efficiency of CPPs and their 
cargo could change drastically when studied under physiological conditions where 
highly precise measurement tools, such as Nuclear Magnetic Resonance spectroscopy 
(NMR), cannot be employed [98, 99].  It is likely additional comprehensive studies 
are required to better understand the specific transduction methods of specific cell-




Endocytosis is a cellular process that facilitates the passage of solutes and 
solvents through the cell membrane.  The four different methods of endocytosis, 
lipid-raft-mediated endocytosis, macropinocytosis, cholesterol-dependent clathrin-
mediated endocytosis, or clathrin-independent endocytosis, are energy-dependent 
mechanisms for permeation of macromolecules across the cell membrane [91, 100-
102].  After transport across the membrane through endocytosis, the CPP-cargo 




pathway energy independent.  Arginine-rich CPPs, such as TAT, first encounter a 
series of negatively charged molecules at the cell surface: carbohydrates (mainly 
glycosaminoglycans), lipids, and membrane proteins.  The positively charged CPPs 
rapidly bind to their negative molecules and facilitate a controlled mechanism for 











Figure 4. Three proposed methods for cell 
transduction of cell-penetrating peptides 
and their cargo: Caveolae/clathrin 
independent endocytosis, caveolae-
mediated endocytosis, and direct 
penetration.  Route 1 is the caveolae/clathrin 
independent endocytosis method.  This 
method is energy dependent, but does not 
require a vesicle to transduce through the cell 
membrane.  Route 2 is the proposed primary 
method for cell transduction through a 
caveolae-mediated endocytosis.  The 
macromolecule is transduced across the cell 
membrane and into the cytoplasm using a 
hydrophilic vesicle.  Most macromolecules 
that are transduced using vesicles will remain 
trapped inside the vesicle.  This method 
initiates with the adhesion of the CPP-cargo to 
a receptor-specific cell membrane protein.  
Route 3 is the direct penetration method that is 
energy independent. 






Endocytosis is temperature and energy dependent 
Wedner et. al. published results confirming the TAT-peptide can transduce cells even 
at 4°C.  At this temperature, all mechanisms that drive endocytosis are paralyzed 
[103]. 
Richard et. al. published results that showed lower efficiency and kinetics of TAT 
transduction at 4°C.  Moreover, when cells were treated with Sodium Azide or 
deoxyglucose (agents that consume cellular ATP), the transduction efficiency and 
kinetics were greatly reduced.  Several studies have confirmed the TAT peptide 
transduces into the cell via numerous methods: endocytosis and direct penetration 
[104].   
 
1.2.4.3 Caveolae-mediated endocytosis requires the adsorption of the CPP-
protein complex to the plasma membrane 
	
Tyagi et. al. published results that confirmed TAT-GFP or TAT-GST cell 
transduction requires the adsorption to cell surface heparin sulfate proteins.  wtCHO-
K1 and wtA-745 cell lines, defective of surface heparin-sulfate could not effectively 
transduce the TAT-protein fusions [105-107]. 
Wedner et. al. published results where they compared three isoforms of the 
TAT-peptide sequence: 49RKKRRQRRR57): the native sequence order with native 
peptide isoforms, the native sequence order with only D-amino acids, and the inverse 
native sequence order with only D-amino acids (57RRRQRRKKR49).  All three 
isoforms had similar transduction efficiency and kinetics which would refute the 




transduction through the cell membrane.  The retro-inverso sequence of the peptide 
(57RRRQRRKKR49) to its native state (49RKKRRQRRR57) [103]. 
 
1.2.4.4 Clathrin-dependent endocytosis requires sufficient potassium and the 
formation of hydrophobic clathrin vesicles 
 
Richard et. al. treated cells with chlorpromazine (an inhibitor of clathrin 
vesicles) and transduced cells in the absence of potassium in the culture media.  The 
inhibition of clathrin vesicles and absence of potassium had a significant effect on the 
transduction of TAT-GFP complexes [104]. 
	
Table 1. Confirming and refuting experimental results of endocytosis, caveolae-
mediated, and clathrin-dependent endocytosis pathways.  All experiments were 
performed using TAT-GFP complexes and showed experimental results either 
confirming or refuting the	potential	transduction	pathway.	
	
	
Ter-Avetisyan G et al. used an ATCC cell line BHK21-tTA/anti-clathrin 
heavy chain that showed efficient transduction of TAT-GFP complexes.  This cell 
line has an inducible anti-clathrin antibody plasmid.  After inducing the cells, the 
Transduction 
Method 
Confirming  Refuting 
Endocytosis Inhibition at 4°C and requires 
ATP [107] 





Heparain adsorption is 
required [105] 
Using all D-amino acids of 
the native sequence as well 
as the D-isoform in a 
reverse sequence 
functioned equally to the 




Clathrin vesicles and 
potassium are required for 
efficient transduction [110] 
Cells expressing anti-
Clathrin antibodies could 





TAT-GFP complexes were co-incubate to show clathrin-independent endocytosis 
[111]. 
	
1.2.4.5 Endosome Escape 
 
Endocytosis of macromolecules will often result in the compartmentalization of 
the molecules inside an endosome.  The endosome is a low-pH environment that 
often facilitates proteolytic digestion by lysozyme.  The digested macromolecules are 
then internalized to a specific cellular location or transported outside of the cell [112, 
113].  For molecules that are released from the endosome, four proposed mechanisms 
have been identified: 
1. Pore Formation:  Proteins or peptides that are trapped in an endosome have 
the potential to bind to specific areas of the membranous wall.  High-affinity 
binding could lead to disruption in the lipid bilayer, causing a localized pore.  
This localized pore is a channel for which molecules inside the endosome can 
freely escape [114, 115]. 
2. Ion Pump:  Proteins or peptides that are localized within the endosome can 
become protonated in the low-pH environment.  If the degree of protonation is 
excessive, the osmotic pressure within the endosome could reach a critical 
limit causing rupture in the membranous wall [116].    
3. Membrane Fusion:  Viral-based peptides or proteins often have fusogenic 
properties as their primary function.  Under physiological conditions 
(pH~7.4), the fusogenic molecules remain inert and non-functional.  However, 




where the protein or peptide will fuse to a lipid bilayer molecule in the 
endosomal membrane.  The fusogenic-effect could cause disruption and 
compromise the integrity of the endosomal membrane leading to leakage 
[117-120].   
4. Synthetic Endosome-Escape Domain (sEED):  Hydrophobic small molecules, 
when fused to proteins or peptides, enhance endosome escape by destabilizing 
the membrane lipid-bilayer.  In a similar mechanism to membrane fusion, 
sEED molecules have a hydrophobic tail that embeds into the lipid-bilayer 
causing destabilization and pore formation.  If a protein or peptide is fused to 
the sEED molecule, the pore formation allows for the release from the 
endosome [121-123].   
For efficient delivery of active biomolecules, the endosome escape must be in a non-
toxic mechanism.  From the above described endosome escape mechanisms, the last 
two, membrane fusion and sEED appear to disrupt endosome membranes, free of 
deleterious pore formation or endosome rupture. 
The two shortcomings of arginine-rich cell-penetrating peptides is the complete 
understanding of transduction mechanisms and the efficiency of endosome escape.  
As described earlier, conflicting publications have provided experimental results to 
describe the specific mechanism of action for cell transduction: energy dependent or 
independent methods.  Secondly, upon transduction of the outer membrane, the cell-
penetrating peptide and associated cargo are often held in an endosomal compartment 
rendering their function useless and inactive inside the cell.  Qian, et al. have 




endosome escape for arginine-rich peptides that have transduced the cell membrane 
[124].  Peptides were chemically synthesized as a linear fragment and then a complex 
reaction, treated with benzotriazole-1-yloxy-tris-pyrrolidino-phosphonium 
hexafluorophosphate for the covalent linkage of the n-terminal and c-terminal amino 
acid.  The cCPP was labeled with a small fluorophore, naphthofluorescein (NF), to 
measure endosome escape efficiency and localized diffusion upon entry to the 
cytoplasm.   
The cCPP binds to an outer membrane phospholipid for endocytosis transduction.  
Energy-dependent endocytosis was confirmed by observing a decrease in 
transduction at lower temperatures.  At 4°C, endocytosis was unmeasurable and 
completely interrupted.  Upon transduction, endosome escape was measured by 
observing the relative fluoresce intensity of NF over time.  NF is a pH-sensitive 
fluorophore with a pKa of 7.8.  Inside the endosome is an acidic environment 
(pH<6.0) which diminishes the fluorescent signal of NF.  Upon endosome escape, the 
cCPP enters the cytoplasm where the pH is ~7.4.  Entering the cytoplasm, the 
fluorescent signal of the NF-labeled peptide increases confirming release in the 
endosome.   
Endosome escape mechanisms are potentially deleterious to cellular function 
from pore formation or endosome destruction [116].  Varkouhi, et. al. proposed a 
mechanism for endosome escape of peptides or proteins where the biological 
molecules are protonated in the acidic endosome causing an influx of hydrogen and 
chlorine.  The influx of the ions causes osmotic pressure in the endosome and 




where the cell substrate was labeled with an endocytosis marker—Rho-labeled 
dextran (dextranRho).  Upon endocytosis transduction, the dextranRho molecule will 
remain entrapped in the endosome.  If co-incubated with a cell-penetrating peptide 
that causes deleterious endosome escape, the dextranRho will co-locate in the 
cytoplasm as escape will be rapid from a porous compartment.  Incubation of 
dextranRho alongside the NF-labeled cCPP resulted in endosome localization of the 
dextranRho-mediated fluorescence, while the NF-labeled cCPP fluorescence was 
throughout the cytoplasm.   
 
1.2.4.6 Cell penetrating peptide structure-function 
 
The first generation of cell-penetration peptides were truncated amino acid 
sequences of naturally occurring proteins or chimeric peptides.  Naturally occurring 
active peptide sequences were the first CPPs discovered and often only a few amino 
acids of a large protein directed translocation.  The natural, truncated CPPs could be 
combined to further enhance their transduction efficiency.  Chimeric peptides were 
often constructed by combining a CPP with a signal peptide introducing cell or 
substrate selectivity [125]  Transportan is a chimeric CPP that is 27 amino acids in 
length: 12 amino acids at the C-terminus from the signal peptide, Galanin, and 15 
amino acids at the N-terminus from the toxic peptide, Mastoparan.  Mastoparan, a 
natural peptide found in wasp venom, directs the translocation of the chimeric 
peptide.  Galanin provides selectivity to neural cell lines [125].  The first class of 




synthetic manipulation to facilitate modified structure and function of the cell-
penetrating peptides.    
The second generation employed amino acid substitution or addition, or the 
covalent linking of side chains to the truncated naturally-occurring CPPs.  The side-
chain modification of CPPs enhanced transduction efficiency or stability, or enhanced 
the stability of the CPP-cargo complex.  Adding hydrophilic groups to an existing 
CPP would enhance its transduction properties.   
 
Figure 5. Second generation TAT-peptide (GRKKRRQRRR) derivatives: amino 
acid substitution, side chain modification, and peptide stereochemistry.  1Vives et 
al. modified the arginine residues at positions 55,56, and 57 through deletions or 
substitutions with Alanine.  For TAT-GFP complexes, these modifications enhance 
internal cell fluorescence indicating a greater transduction efficiency[126].  2Wender 
et al. also modified the arginine residues at 49,52,53,55,56,57 and the Lysine residues 
at position 50.  Moreover, the CH2-side chain of Arginine 56 was extended.  These 
changes also enhanced the internal cell fluorescence.  The use of only D-amino acids, 
and the inverse amino acid sequence using only D-amino acids did not change the 
internal cell fluorescence[109].  3Umezawa et al. synthetically modified the amide 
bond between the C-terminal Glycine (48) and Arginine 49[127].  4Mitchell et al. 




fluorescence[128].  5Futaki used the amino acid substitutions from Mitchell et al. and 
used only D-amino acids to observe similar cell fluorescence[129].  Figure adopted 
from Vives et al. [130]. 
The third generation are completely synthetic peptide sequences developed by 
computer models or empirical scientific design and execution.  These types of CPPs 
involve predictive amino acid sequences that are based on structure-activity studies of 
peptides: most CPPs are comprised of positively charged amino acids, have low 
hydrophobic interactions with membrane proteins, and are generally 15-25 amino 
acids in length.  Arginine residues contribute to cell transduction potential of CPPs 
more than lysine groups [125]most likely due to the ability of the extra hydrogen 
bond donation from the side chain guanidine.  Guanidine is a strong base and is 
rapidly protonated under physiological conditions [86].  Secondly, if the hydrophobic 
interactions of the cell membrane proteins and the CPP are too high, transduction 
efficiency is reduced [108, 131].  Finally, the last aspect of a CPP is the short length 
of the amino acid sequence, as the 13-amino acid TAT peptide is truncated from the 

















3rd Polyarginine Empirical	discovery Rn,	n=	8	or	9  




sequences	that	exhibit	the	properties	of	naturally-occurring	CPPs.   
 
Modeling the kinetics of cell transduction by cell-penetrating peptides and 




!""'()*+(,%'-*.			   [Equation 1] 
 
CPPbulk is assumed to be a uniform concentration of the peptide-macromolecule in the 
bulk phase.  The bulk phase-cell membrane is assumed to be free of concentration 
gradients and macromolecules rapidly diffuse to and from the cell membrane without 
resistance.  Moreover, the bulk concentration is assumed to be significantly higher 
than the maximum concentration of internalized CPP.  To measure the first-order rate 
constant, samples from the bulk phase can be measured for CPP concentration over a 
duration of time where an equilibrium has been reached and the bulk concentration 




Experimental conditions can also deduce the impact of structural changes (or amino 
acid modifications) of the CPP by altering the bulk concentration, temperature, bulk 
composition, cell type, or pH of the bulk phase.  Different experimental conditions 
can alter the first order rate constant, k, which can be calculated through the first-
order rate kinetics equation: 




      [Equation 3] 
 
An additional parameter than can be useful in determining the effectiveness of a CPP-
macromolecule or different environmental conditions is the half-time of 
internalization [t0.5internal] [134, 135].  This can be calculated from the rate constant, k, 
in Equation 2.  Since the kinetics of internalization are quite rapid, precise and time-
sensitive measurements need to be employed to accurately measure the concentration 
of the CPP-macromolecule either in the bulk phase or internalized. 
1.2.5 HIV-transcription activating factor 
 
The HIV-transcription activating factor, or TAT, is a protein responsible for 
the replication of HIV.  Comprising of 86-102 amino acids (depending on the specific 
viral serotype), three distinct structure-function regions are encoded: the 
transactivation region, a DNA-binding region, and a nuclear import region.  The 
nuclear import region has the specific ability to transport macromolecules across the 
cell membrane.  It also can deliver calcium-independent binding of proteins to the cell 
membrane.  In its native state, the Tat protein is routinely secreted and transduced 




protein localizes in the cytoplasm and nucleus [136].  Some studies have shown TAT 
transduction is time and	temperature	dependent	leading	to	endocytosis	[137].		
However, other studies have shown temperature independent transport leading to 
direct penetration [138]. 
 
1.2.5.1 Bioactivity and pre-clinical models 
 
Cell-penetrating peptides are generally believed to have low cytotoxicity; 
however, a new class of peptides have shown the dual ability to penetrate cell 
membranes of tumor cells and induce apoptosis.  The tumor suppressing protein, 
p14ARF, has a 22-amino acid motif on the n-terminal region to has shown pro-
apoptotic activity.  Moreover, the CPP transduces the cell membrane through 
endocytosis. 
Pre-clinical models: 
1.  Peritoneal carcinomatosis and peritoneal lymphoma in animal models were 
treated with a TAT-fused peptide, RI-TAT-p53C’, that provided lifetime 
extension as well as a disease-free model [139]. 
2. Bladder cancer tumors expressing the mutant form of protein, p53, were 
treated with HA2-fused proteins, T24 and J82, that increased the survival time 
of animal models [140].    
3. Human glioma-initiating cells were effectively transduced with the flock 
house virus cell-penetrating peptide (FHV) fused to an apoptosis inducing 
protein, dPasFHV-p53C0.  The study concluded the fusion of auto-
phagosomes with lysosomes was prevented after transduction of the CPP-




1.2.5.2 Clinical studies using cell penetrating peptides for therapeutic delivery 
 
Capstone Therapeutics:  AZX100 is a 23-amino acid that rapidly transduces 
human fibroblast cells and enhances the expression of phosphor-caveolin (Y14).  
Capstone executed a Phase IIa clinical trial to evaluate the efficacy of AZX100 in 
preventing scarring after arthroscopic shoulder surgery.  The clinical trial was a 
double-blind, randomized study tested intradermal administration of the peptide or 
saline at day 9 and/or 21 after surgery.  Scar color, size, pain, and morphology (after 
surgical removal of small tissue samples) were evaluated to determine the 
effectiveness of AZX100 in comparison to saline.   Unfortunately, the product was 
discontinued as a clinical model after the effectiveness of AZX100 could not be 
distinguished from the placebo [142]. 
ReVance Therapeutics:  A proprietary peptide sequence inserted at the N-
terminal and C-terminal regions of the 150kDa onabotulinumtoxinA protein (botox).  
From transdermal application (RT001), the flanking peptides permit transduction 
through multiple layers of epidermis cells as the peptide functions as a cell-
penetrating peptide.  When delivered subcutaneously (RT002), the flanking peptides 
rapidly transduce the protein into the epidermis cells and thus control the diffusion of 
the botox protein to unwanted tissue.  ReVance executed a Phase IIIa clinical trial to 
evaluate the effectiveness of their peptide-protein complex to reduce the appearance 
of fine lines around the eyes—glabellar lines.  The clinical trial was a double-blind, 
randomized study that unfortunately did not show effectiveness of the peptide-botox 
complex superior to botox alone [143].  ReVance currently has an active Phase II 




[144], and an active Phase II clinical trial to study the effectiveness in RT001 in 
preventing axillary hyperhidrosis [145].  
Amgen:  Etelcalcetide is an 8-amino acid synthetic peptide that has side chain 
modifications to enhance the function of the cell-penetrating peptide.  A single L-
Cysteine is bound through a disulfide bridge to 7 amino acid peptide backbone.  The 
seven amino acids in the backbone chain are all D-isomers, whereas the single 
Cysteine is an L-isomer [146].  The peptide was studied in a phase 3 clinical trial to 
treat secondary hyperparathyroidism (sHPT) in adult patients with chronic kidney 
disease that are currently on dialysis.  The peptide activates calcium-sensing receptors 
which in turn decrease excess secretion of the parathyroid hormone (PTH).  Excess 
PTH in the blood stream leads to an excess concentration of calcium and phosphorus 
in the bones.  The European Medicines Agency (EMA) provided Amgen a positive 
opinion on behalf of the Committee for Medicinal Products for Human Use (CHMP) 
in September 2016 [147].  (FDA) rejected the peptide as an approved product in 
August of 2016 after an extensive Phase III clinical trial[148].  Amgen has submitted 












Table 3. Active and terminated clinical studies using cell-penetrating peptides.  
All clinical studies passed the phase I clinical trial confirming the low cytotoxic 
mechanism that cell-penetrating peptides transduce into the cell.  However, several 
clinical studies were halted due to efficacy.   
 

































































































1.2.6 Protein Stability and Thermodynamics 
 
Thermal stability of a protein can be theoretically predicted by calculating 
conformational entropy.  The conformational entropy can be estimated based on the 
limited number of accessible conformations possible by a protein—linear and circular 
motifs [152, 153].  Using the Gibbs free energy equation and conformational 
probability (Equation 4 and Equation 5), we can estimate the reduction in 
conformational entropy; 
< =, ? = 	@ + =B − ?C   [Equation 4] 
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Empirically, we can measure the thermal stability of a protein through its enthalpy of 
transition (Equation 7).  Using differential scanning calorimetry (DSC), the target 
protein can be heated beyond a temperature that denatures and unfolds the 
protein[154-156].  This transition temperature determines the relative thermal 




        [Equation 8] 
The transition temperature of the unfolding state can empirically confirm the 
increased thermal stability of a circular protein in comparison to its linear counterpart.   
1.2.7 Proteases  
 
Proteases are naturally occurring enzymes that function to digest native or non-




decreasing the overall yield.  The specific activity of proteases can be divided into 
their region of protein digestion—endopeptidases digest internal amino acids, 
whereas exopeptidases digest terminal amino acids [157].  Carboxypeptidase-A 
(CpA) is an exopeptidase that digests the C-terminal amino acid of a protein.  If a 
protein is expressed as a circular motif, it lacks a C-terminal amino acid, and would 
be protected from CpA [158].   
 
1.2.7.1 Protease degradation of internalized CPP-protein complexes 
 
Internalized CPPs through endocytosis are often trapped within the endosome or 
if endosome-escape is facilitated, the macromolecule is susceptible to protease 
degradation.  For CPP-protein complexes that target nuclear localization, protease 
degradation often causes the accumulation of transduced molecules in the cytoplasm 
[159].   
1.2.8 Present Study 
 
This present study examined the potential of an engineered fluorometric 
reporter system’s cell transduction potential.  This novel reporter system combined 
the background theory and relevant literature research of three isochronic post-
translational features: (1) a cyclical protein, (2) a cell-penetrating peptide, and (3) a 





Chapter 2: A fluorescent, cyclized, protein-peptide fusion of 
an active subunit of ß-hCG exhibited low in vitro 





Maternin, a 14-amino acid subunit of ßhCG, exhibited in vivo efficacy of 
tumor reduction and low toxicity on patients with AIDS-related Kaposi’s sarcoma in 
a phase I/II clinical trial.  The active peptide was synthesized and showed comparable 
colony reduction rates to taxol when treated against PC-3 (prostate), HTB-123 
(breast), and KSY-1 (epithelial) cell lines.  A peptide, in a complex environment such 
as the human body, can experience thermal, enzymatic, and chemical degradation.  
Moreover, the potential for the peptide to fail to reach the target is also a significant 
hurdle.  In this study, Maternin was expressed as an eGFP-fusion protein, utilizing the 
split-intein expression system.  The purified fusion protein was co-incubated with PC-
3, HTB-123, and KSY-1 cells at 1.0µg/mL, 0.5µg/mL, and 0.1µg/mL.  An eGFP, 
split-intein fusion, absent of Maternin, and PBS were used as a negative control.  
Synthetic, cyclized Maternin (mono-disulfide bridge) produced by Aapptec 
(Louisville, KY) and Taxol, a widely utilized, anti-carcinoma agent was used as a 
positive control [160-162].  Both control groups were tested at 1.0µg/mL, 0.5µg/mL, 
and 0.1µg/mL.  Survival fraction, to PBS control for 1.0µg/mL, 0.5µg/mL, and 
0.1µg/mL respectively: Taxol, 24.7 (±1.81), 16.7 (±2.24), 9.32 (±1.30); Synthetic 
Maternin, 28.9 (±1.39), 15.6 (±0.98), 9.89 (±1.39), eGFP-Maternin, 87.5 (±2.24), 




eGFP-Maternin did not exhibit the high cytotoxicity as taxol or synthetic, cyclized 
Maternin, however, the high survival rates of the cell lines denote the low 




 KSY-1 is a cell line derived from the pleural fluid of a human patient with 
AIDS-related Kaposi’s sarcoma.  This cell line induces tumors, angiogenesis, and 
metastases when injected into immunocompromised mice (scid).  However, when 
injected into pregnant scid mice, tumor proliferation is inhibited.  This led to the 
discovery of an active sub-unit of the pregnancy hormone, b-hCG—Maternin.  
Maternin, a 14-amino acid molecule, exhibited efficacy in tumor reduction in vitro 
and in vivo [162]. 
During the discovery phase of Maternin, several preparations of ß-hCG were 
isolated.  These preparations were all small peptide molecules (< 35 amino acids) and 
exhibited varying effectiveness in tumor suppression.  The active preparations also 
exhibited a positive dose-response correlation.  The parent molecule, ß-hCG, did not 
show in vitro efficacy.  Figure 6 illustrates the dose-response of Maternin in the phase 
I/II clinical trial of AIDS-related Kaposi’s sarcoma patients.  Figure 7 illustrates the 
in vitro efficacy of tumor cell inhibition of several Maternin-related sequences, all 






Figure 6. In vitro efficacy of colony forming unit inhibition of KSY-1, PC-3, and 
HTB-123 using preparations of ß-hCG, from Gill, et.al. (1996)[162].  The parental 
molecule, ß-hCG, tested as a natural and recombinant-expressed molecule, exhibited 
minimal colony formation inhibition.  The five preparations of Maternin, MAs2 
(synthetic Maternin, alternative sequence 2), MA (synthetic Maternin, sequence 2), 
AA21-52 (sub-unit of ß-hCG, amino acid sequence 21-52), MAs1 (synthetic 
Maternin, alernative sequence 1), and MAs3 (synthetic Maternin, alternative 





 Clinical studies for Maternin were terminated for unknown reasons.  It can be 
speculated that a lack of efficacy or dose-dependency could not be verified in a 
controlled, clinical-study.  A low efficacy in clinical studies could be due to low 
activity of the molecule, or low bioavailability.  A cyclized, peptide-protein fusion 
could enhance the stability of the peptide and increase bioavailability.  In this study, 
Maternin was expressed as a fusion partner to eGFP, using the intein-based system 
for a cyclized, peptide-protein fusion.  In vitro efficacy was studied using a 
clonogenic assay.  Three carcinoma cell lines, used in previous efficacy studies for 






Figure 7.  Carcinoma lesion size response after treatement with an active sub-
unit of ß-hCG.  Table from Gill, et al. (1996)[162].  A dose-response can be 
denoted from the treatement of Maternin on AIDS-related Kaposi’s sarcoma patients. 
 
 Peptide therapeutics create significant challenges for clinical studies and 
eventual commercialization.  The primary route of administration for peptide drugs is 
oral delivery.  Since peptides are rapidly degraded when entering the stomach by 
gastric acid and peptidases in the blood, bioavailability is s significant hurdle [163].  
Cyclizing peptides has enhanced bioavailability in recent studies [164].  However, 
inclusion of a fluorometric reporter to a peptide-protein fusion could be a functional 





2.3 Materials and Methods 
 
To generate a purified protein, E. coli codon optimized genes (Appendix 1) were 
prepared and proteins were expressed in competent cells.  The proteins were purified 
using a two-column platform and then dialyzed into PBS for clonogenic assays.  The 
clonogenic assay is an effective analytical tool for measuring the capacity of a 
compound to inhibit tumor proliferation in carcinoma cell lines.   
2.3.1 Protein Expression 
 
Rosetta (DE3) Competent cells (Novagen/Millipore, Billerica, MA) were transformed 
with purified plasmids, as described in Appendix A.  A single colony was inoculated 
into LB-media (BD, 30g/L) and incubated overnight at 37°C and 225 rpm (1’’ stroke 
length).  The overnight culture was centrifuged at 5000rcf for 10 minutes.  The pellet 
was inoculated at 1% (v/v) into LMR media (Appendix G.1), and incubated at 37.0°C 
and 225 rpm.  At A600 ~ 1.0, the culture was rapidly chilled to 16.0°C and induced 
with 0.5µM IPTG.  The induced culture was incubated for 16 hours at 16.0°C and 
225rpm and then centrifuged at 5000rcf for 10 minutes.  The pellet was lysed in 4mL 
buffer/g pellet, of IMAC Load/Lyse buffer (Appendix G.2) using a microfluidizer, set 
at 30,000psi using 3 passes.  The lysate was centrifuged at 30,000rcf for 30 minutes.  
The supernatant was recovered and further purified.  
 
2.3.2 IMAC Purification 
 
Fast flow sepharose (Amersham, Waltham, MA) was loaded onto a gravity column 
and washed with H20 for 10 column volumes (CV).  5CV of 100mM NiSO4 charged 




Lysate (From 3.3.1) was gravity fed onto the column and flow-through was 
discarded.  The column was washed with 10CV of IMAC wash buffer and discarded.  
The column was eluted using 1CV additions of IMAC elution buffer and further 
analyzed for target protein concentration using fluorescence.  Fractions without target 
protein were discarded. 
 
2.3.3 Concentration/Dialysis of Protein Solutions (target protein >30kDa) 
 
Dialysis of elution fractions was performed using a 10kDa centrifuge column 
(Millipore, Billerica, MA).  Elution fractions were first concentrated to 10% of the 
filter capacity by centrifuging at 5,000rcf.  90% of the filter capacity was replaced 
with 1xPBS, pH 7.4.  The filter was centrifuged at 5,000rcf until 10% of the filter 
capacity was reached.  The concentration and dialysis was repeated a total of 3 times.  
The resulting retentate fraction was recovered and stored at 2-8°C. 
 
2.3.4 Size Exclusion Purification of eGFP-variants 
 
A Superdex-75 10/300GL SEC column (GE, Fairfield, CT) was washed with 2CV of 
1xPBS, pH7.4 at 0.5mL/min.  250µL of protein solution was loaded onto the column 
at 0.5mL/min and further washed with 1xPBS, pH7.4.  Flow-through and wash 
fractions were collected in 250µL fractions.  Flow-through was monitored using 






2.3.5 Clonogenic Assay 
 
PC-3, HTB-123, and KSY-1 (cell lines from Institute of Human Virology, University 
of Maryland-Baltimore, Baltimore, MD) were cultured in RPMI (Invitrogen, MD), 
containing 15% fetal calf serum and incubated at 37.0°C and 5% CO2.  Cells were 
harvested using 0.4% trypsin and magnetically sorted for cells expressing CD133+ 
(cancer stem cell marker) and CD44+ (cell-surface glycoprotein) using a LS Column 
(Miltenyi Biotec, San Diego, CA).  200 viable cells with positive CD133+/CD44+ 
markers were plated in a 24-well plate and incubated overnight.  The media was 
aspirated and replenished with fresh media containing the target compound.  The 
plate was incubated for 7-days in a humidified environment.  The cells were stained 
with 0.5% Gentian Violet in methanol and scored as dead if the colony formation was 
< 25 cells. 
 
2.4 Experimental Design 
 
 
Clonogenic cell survival assay (clonogenic assay) can determine the 
effectiveness of a compound’s inhibition of cancer cell survival and proliferation.  A 
clonogenic assay’s metric is the inability of a single cell to form a colony of > 25 
progeny cells.  Cells unable to form a colony are considered dead, in contrary to the 
metric the trypan-blue exclusion method.  A typical trypan-blue assay measures the 
porosity of a cell membrane.  A non-viable cell will have a porous membrane 
permitting trypan blue stain penetration [165, 166].  However, cell can also retain its 
ability to synthesize DNA and proteins, and even execute one or two mitoses, but 




trypan-blue assay, but this is considered a dead cell using a clonogenic assay [167-
169].  Therefore, a compound could be effective in inhibiting colony formation, yet 
considered viable.  For clonogenic assays measuring a compounds effect on tumor 
suppression, a clonogenic assay is a more effective metric for effectiveness.   
The clonogenic assay in this experiment included two control arms.  The 
positive control arm included a cyclical synthetic Maternin and taxol.  The cyclical 
synthetic Maternin was produced by Aaptec.  The cyclical peptide was synthesized 
using an S-S bond between the N-terminal and C-terminal amino acids.  Taxol, a 
common clinical anti-carcinoma agent was the second positive control group.  The 
negative control arm included PBS (1x, pH 7.4) and (C)eGFP (absent of Maternin).  
After the 7-day incubation with the compounds the stained plates were analyzed for 
plating efficiency and colony survival. 
To verify the identity of the carcinoma cell lines, the cells were positively 
selected for two key cell markers: CD133+ and CD44+.  CD133+ is a key marker of 
cancer stem cells.  Expression of CD133+ is indicative of a progenitor cell capable of 
cell division and tumor-initiation capacity [170, 171].  CD44+ is a multi-functional 
cell surface molecule, involved in cell proliferation, division, and signaling [172]  
Cancer cells expressing CD44+ indicate the capability of pathogenic activities [173].  
A clonogenic assay using cells with positive CD133+ and CD44+ markers, employs an 
orthogonal selection method for a carcinoma cell line capable of tumor formation.   
The compounds tested in a clonogenic assay must be relatively pure and in a 
physiologically inert matrix.  Protein impurities, sourced from the host-cell, that have 




two-column purification strategy.  In this experiment, the primary capture column is a 
Ni2+-charged IMAC column.  Proteins containing a polyhistidine-tag will readily bind 
to the column.  The secondary, polishing column, is a size exclusion column (SEC).  
The SEC column will further purify the target protein from impurities that co-eluted 
from the IMAC column.  This is an essential step for intein-based proteins as the 
artifacts from the protein ligation (unprocessed inteins, Nintein fragment, and Cintein 
fragment) will co-elute with the target, cyclized protein on the Ni2+-charged IMAC 
column.  The SEC column mobile phase is PBS, a physiologically-inert buffer with 
low cytotoxicity.  This allows for the elution fraction of the SEC column to be 
immediately utilized in the clonogenic assay.   
It was hypothesized the (C)Maternin-eGFP compound would function to 
suppress carcinoma cell proliferation.  The clonogenic assay would function to 
compare the (C)Maternin-eGFP compound to Taxol and cyclized, synthetic Maternin, 
two compounds that have shown in vitro efficacy in tumor suppression using a 
clonogenic assay.  Previous clonogenic assays, testing cyclized synthetic Maternin 
and taxol have shown 60% colony inhibition (40% survival) at 0.1µg/mL and >80% 
colony inhibition (<20% survival) at 0.5µg/mL [174].  A cyclized, eGFP-Maternin 
that inhibited colony formation in carcinoma would provide a therapeutic model to 










2.5 Results and Discussion 
 
This experiment was executed in two phases: the production and purification of 
(C)eGFP and (C)Maternin-eGFP recombinant proteins and the execution of a 
clonogenic assay to measure the effectiveness of the recombinant proteins of 
inhibiting cancer cell proliferation.   
 
2.5.1 Protein Production and Purification 
 
Recombinant proteins, (C)eGFP and (C)Maternin-eGFP, were expressed as described 
in 3.3.1 and purified using an IMAC-Ni2+ column as described in 3.3.2.  The elution 
fraction from the column was concentrated and dialyzed into PBS as described in 
3.3.3 and then purified using a SEC column as described in 3.3.4.  Elution fractions in 
Figure 8 that correspond to the protein gel lane #6 were analyzed for protein 
concentration using a Bradford Assay (Biorad 5000001) and adjusted to 100µg/mL 
using PBS.  Two additional concentrations were prepared, 50µg/mL, 10µg/mL by 
diluting the 100µg/mL with PBS.   
 The post-translational modification of the split-intein system produces several 
artifact proteins.  As observed in Figure 8, a linear eGFP protein can be observed in 
the elution fraction of the reduced and non-reduced alongside the cyclized eGFP.  
Since the cyclized eGFP has a reduced conformational entropy as described in 
Equation 7, the amount of exposed charge groups is less.  Since the amount of 
charged groups on a protein is directly correlated to the residence time in a SDS-
PAGE gel, the cyclized protein will migrate faster than the linear protein.  In Figure 




and a denatured (Lane 5).  In both lanes, two proteins can be observed at 
approximately 27kDa.  Both proteins emit fluorescence.  The IMAC column provides 
an enriched fraction of the cyclized GFP protein.  
 A SEC column enhances the purification of the cyclized eGFP elution fraction 
from the IMAC column.  Since all protein artifacts from the split-intein system will 
have eGFP, it is necessary to use a non-affinity based purification method to separate 
the GFP fractions.  In Figure 9, the SEC column can enhance a specific fraction for 
the cyclized eGFP fraction as observed in the corresponding protein gel.  The molar 
ratio of the linear and cyclized protein appears to be uniform in the IMAC elution 
fraction, however, in SEC fraction 6, there is significantly more cyclized eGFP than 
linear eGFP.   The SEC column is an effective purification tool for purifying an 






Figure 8. IMAC-Ni2+ Purification of (C)eGFP Lysate.  The lysate of a (C)eGFP 
expressed E. coli culture was purified on a IMAC-Ni2+ and eluted to enhance the 
cyclized eGFP protein.  Lane 5, the column elute, would be furthur purified on a SEC 
column.  The protein gel is a 10-20% Tris-Glycine gradient gel.  The sample was 
mixed equally with 2x Laemmli Buffer (+ßME).  Lane 6 is the column elution sample 
under non-reducing conditions.  The sample buffer did not contain ßME and the 








Figure 9.  Size-
Exclusion purification 
of (C)eGFP IMAC 
elution fraction 
samples. The fractions 
in the SEC column were 
widely used in this 
document.  The fraction 
loaded onto Lane 3 is the 
unpurified intein 
fraction.  The fraction 
loaded onto Lane 6 of 
the gel is the purified 
cyclic protein sample.  
The fraction loaded onto 
Lane 7 is a diluted Lane 
3 fraction spike into the 
Lane 6 fraction.  The 
protein gel is a 4-15% 
Tris-Glycine gradient 
gel.  The samples are 
mixed equally with 2x 







Lane Sample Description 
1 Protein Ladder (Biorad 1610324) 
2 SEC Fraction #1 
3 SEC Fraction #2 
4 SEC Fraction #3 
5 SEC Fraction #4 
6 SEC Fraction #5—Enhanced cyclized eGFP fraction 
7 Diluted SEC Fraction #1 spiked into SEC Fraction #4 
Table 4.  SEC fraction description of (C)eGFP IMAC elution.  The IMAC 
elution sample was purified on a SEC column.  Proteins were purified using an 
SEC column, smaller proteins migrate faster through the column.  Fraction 2 and 3 in 
the table contain an enhanced Cintein-eGFP fraction which is unwanted.  Fraction 4 is 




2.5.2 Clonogenic Assay 
 
 The clonogenic assay tested the effectiveness of several compounds on cancer 
cell proliferation.  The experiment’s two positive controls: Synthetic (cyclical) 
Maternin, and Taxol were tested at three different concentrations: 1.0µg/mL, 
0.5µg/mL, and 0.1µg/mL.  The two positive control arms inhibited colony formation 
for all three cell lines: KSY-1, PC-3, and HTB-123 under a dose-dependent response.  












    Equation 10 
 
The purified (C)eGFP did not inhibit carcinoma cell proliferation in the 
clonogenic assay.  It was expected the (C)eGFP would function as a negative control 
in the assay and produce a survival fraction close to the test control of PBS.  The 
primary function of the (C)eGFP control was to determine the relative cytotoxicity of 
the Intein backbone for peptide-delivery of the Maternin compound.  If the (C)eGFP 
had induced cytotoxicity during the clonogenic assay, then it would be difficult to 
ascertain the primary mechanism of action of the carcinoma growth inhibition.   
The purified (C)Maternin-eGFP did not inhibit carcinoma cell proliferation in 
the clonogenic assay.  The purified protein had low cytotoxicity, comparable to the 
(C)eGFP survival fractions.  Therefore, based on the positive control of the synthetic 
Maternin and the negative control of the (C)eGFP, it can be concluded the cyclized 





Figure 10.  Compound dose-response semi-log plot of Synthetic Maternin and 
Taxol after 7-days incubation with PC-3, HTB-123, and KSY-1 cell lines.  Three 
concentrations of Maternin and taxol were incubated with PC-3, KTB-123, and KSY-
1 for 7 days and the survival fraction was determined. 
 
  
Figure 11.  Survival Fraction of KSY-1 Cells after 7-day incubation with 
1.0µg/mL, 0.5µg/mL, and 0.1µg/mL of PBS (Control), Taxol, Synthetic 
Maternin, (C)Maternin-eGFP, and (C)eGFP.   KSY-1 cells were incubated with 
compounds for 7 days and then examined for colony proliferation.  Taxol and 
Synthetic Maternin inhibit colony profileration where as the (C)Maternin-eGFP and 
(C)eGFP appear to exhibit low cytotoxicity on the cancer cell lines.  The results 










































Figure 12. Colony Forming Units of PC-3 Cells after 7-day incubation with 
1.0µg/mL, 0.5µg/mL, and 0.1µg/mL of PBS (Control), Taxol, Synthetic 
Maternin, (C)Maternin-eGFP, and (C)eGFP.  PC-3 cells were incubated with 
compounds for 7 days and then examined for colony proliferation.  Taxol and 
Synthetic Maternin inhibit colony profileration where as the (C)Maternin-eGFP and 
(C)eGFP appear to exhibit low cytotoxicity on the cancer cell lines.  The results 























Figure 13. Colony Forming Units of HTB-123 Cells after 7-day incubation with 
1.0µg/mL, 0.5µg/mL, and 0.1µg/mL of PBS (Control), Taxol, Synthetic 
Maternin, (C)Maternin-eGFP, and (C)eGFP.  HTB-123 cells were incubated with 
compounds for 7 days and examined for colony proliferation.  Taxol and Synthetic 
Maternin inhibit colony profileration where as the (C)Maternin-eGFP and (C)eGFP 
appear to exhibit low cytotoxicity on the cancer cell lines.  The results shown are are 










































The purified (C)Maternin-eGFP did not inhibit colony formation of carcinoma 
cell lines in a clonogenic assay.  It was expected the cyclized Maternin-eGFP would 
function similarly to the cyclized synthetic compound.  However, two conclusions 
can be deduced from the experimental results:  first, the (C)eGFP backbone has low 
cytotoxicity to carcinoma cell lines, and second, the Maternin compound requires 
intracellular delivery for efficient function. 
The in vitro test of a therapeutic protein is an essential gateway to clinical 
studies.  Execution of an in vitro test with the properly designed set of positive and 
negative controls allows for the most essential conclusions to be drawn from the 
experiment.  In this experiment, the positive controls functioned to inhibit colony 
formation, and the negative controls did not inhibit colony formation.  One of the 
controls, the (C)eGFP was a successful control.  The delivery mechanism of the 
proposed therapeutic protein was determined to have low cytotoxicity.  Essential in 
determining proper mechanism of action, a scientist must rule out all extraneous 
conditions and variables to conclude their target protein functions properly.  For this 
experiment, the delivery mechanism of Maternin—cyclized and as a fusion partner to 
eGFP, did not induce cytotoxicity.  Therefore, the delivery mechanism can still 
function as a fluorometric tool for future clonogenic assay studies. 
 Maternin has low effectiveness when presented to the extracellular domain of 
carcinoma cell lines.  When presented as a stand-alone peptide, Maternin can freely 
penetrate the cell membrane of a carcinoma cell.  The stand-alone peptide has 




when tagged to a larger fusion-protein, the peptide is non-functional.  Since eGFP is 
too large to freely penetrate a cell membrane, a Maternin-eGFP fusion protein will 
only interact with a carcinoma cell’s extracellular domain.  For a Maternin-eGFP 
fusion protein to inhibit colony formation, it must penetrate the cell membrane.   
 If transduced across the cell membrane, a Maternin-eGFP fusion could offer 
enhanced potency of the molecule.  Peptides are rigid structures that typically do not 
fold to form tertiary structures.  A fusion of Maternin and a larger protein could create 
artificial tertiary structures in the small peptide.  It is possible the new tertiary 




Chapter 3: Thermal, chemical, and enzymatic stability of a 
cyclical, cell-penetrating fluorometric reporter system  
3.1 Abstract 
 
 Forced degradation is a technique employed by biopharmaceutical companies 
during drug development.  Stability of the target protein is an essential characteristic 
to support clinical modeling and lifecycle predictions for commercialization [175].  
The stress conditions tested for a protein stability program can be defined by 
regulatory guidelines [176] or by the individual company sponsoring a protein 
therapeutic.  The protein stability program is introduced early in the drug 
development cycle to ensure comparability of efficacy and safety testing in research, 
manufacturing, and clinical environments [177].  The first stage in drug development 
is the candidate selection phase.  During this phase, a broad stability program is 
executed on lead candidates to help define studies that will enhance the formulation 
matrix of the protein.  This formulation matrix will provide enhanced stability for the 
protein when exposed to thermal, chemical, and enzymatic conditions that induce 
protein degradation [178-180].  Since degradation patterns under physiological 
conditions could have year-long time scales and half-life degradation patterns, 
enhanced or extreme conditions are employed to rapidly determine the relative 
stability of a protein.  Although a protein may never experience temperatures 
exceeding refrigeration conditions (2-8°C), a stability test may incubate the protein at 
37.0°C to understand the thermal degradation patterns under accelerated conditions 
[181].  A second stress-test a stability program could employ would introduce the 




chaotropic effects. A broad understanding of the long-term effects of GuHCl could 
better define a protein stability matrix [182].  
Early drug development candidate screening stability studies require assays 
utilizing reporter systems with short-time scales.  In this study, a fluorometric reporter 
system can analyze accelerated stability studies, under forced degradation conditions, 
using real-time analysis. A cyclical, cell-penetrating peptide-protein fusion is exposed 
to four conditions that typically induce protein degradation: in vitro conditions during 
protein expression, chaotropic agent protein degradation, thermal stability under 
physiological conditions, and exopeptidase digestion.  The cyclical protein, 
(C)TATeGFP, has a eGFP-fusion that functions as the fluorometric reporter.  For in 
vitro stability, the (C)TATeGFP protein exhibits enhanced half-life stability during 
protein expression in relation to the wild-type TATeGFP and eGFP; (C)TATeGFP 
exhibited enhanced equilibrium time during protein expression in relation to the wild 
type TATeGFP and eGFP.  For GuHCl stability, at 5.0M the (C)TATeGFP had 
enhanced half-life stability in relation to the wild type TATeGFP and eGFP, at 3.0M, 
the (C)TATeGFP had enhanced half-life stability in relation to the wild type 
TATeGFP and eGFP.  The (C)TATeGFP offered minimal half-life stability at 1.5M 
GuHCl in relation to the wild type TATeGFP and eGFP.  For thermal stability at 
37.0°C, the (C)TATeGFP did not enhance half-life stability in relation to the wild 
type TATeGFP and eGFP.  Finally, the cyclical protein had no observed digestion 
from carboxypeptidase A.  The cyclical, peptide-protein fusion is a fluorometric 







 This experiment was designed to measure the stability of a cyclized 
fluorometric reporter to enzymatic, thermal, and chemical degradation. eGFP has 
been extensively studied as a fluorometric reporter for in vitro and in vivo assays.  
Since fluorescence is a non-invasive, on-line measurement, the fluorometric reporter 
can serve as a correlation to native state folding of eGFP.  The initial reading of eGFP 
fluorometric reporter assays would be considered its most native state.  A condition 
that would affect the stability of the native state or induce cleavage, would 
theoretically decrease the fluorescence.  In the assay, this would be read as a decrease 
in fluorescence, and measured in real-time under non-invasive conditions.   
It is hypothesized, the covalent bond between the N-terminal and C-terminal 
amino acid in the cyclized eGFP protein will form a more constrained secondary 
structure in the native protein.  A more constrained structure will have less flexibility 
and decreases the opportunity for susceptible hydrophobic regions from exposure to 
denaturing conditions.  Moreover, the constrained structure will experience a reduced 
conformational entropy as discussed in Section 1.6.  The covalent bond will also 
remove the opportunistic activity of exopeptidases that target N-terminal and C-
terminal amino acids.  This study will present a cyclical fluorometric reporter and its 
linear, wild-type counterpart to forced degradation conditions to observe stability 
enhancement of the new system.   
To monitor the relative stability of eGFP variants during protein expression, 
cells are monitored for fluorescence in real-time, while maintaining optimal growth 




on-line fluorescence to report maturating of a synthesized protein.  Since several 
factors contribute to the relative fluorescence of a culture: promoter strength, cell 
metabolism and growth kinetics, temperature stability of the native-folded eGFP, and 
protease activity of the cells.  The cell density of the culture can be monitored by A600 
and native-folded eGFP can be monitored by fluorescence, relative fluorescent units 
[RFU] (480ex/516em filter.)  By combining these two metrics, fluorescence can be 
analyzed as a function of optical density, RFU*A600-1, and the specific fluorescence of 
individual cells can be measured.  Leveau and Lindow published results that analyze 
the rate of change of the individual cell fluorescence ( .ÑÖÜ
.áràââ
) as the slope of a linear 
plot of RFU as a function of A600.  Their results conclude that a mathematical 
relationship can be defined that estimates the relative degradation of eGFP during 
protein expression.   
The Gibbs free energy equation, <	=,?=	@+=B−?C   [Equation 4], is a 
function of temperature.  Each protein’s native state is most favored, when the 
difference of the denatured and native state free energies is most positive.  Since 
enthalpy and entropy are temperature-dependent functions, incubation of a protein at 
a temperature above its native state will cause unfolding and eGFP fluorescence 
degradation.  The cyclical proteins are exposed to forced degradation at 37.0°C for a 
prolonged duration under in vitro conditions of protein expression and absent of cells.  
Halter, et. al. performed a live cell imaging analysis of fibroblasts transfected with 
eGFP.  Protein expression was halted using cyclohexamide.  The non-cyclical, eGFP 
could be modeled by first-order decay kinetics with a fluorescence half-life of 2.8h 




reported results of 26 hours [184].  This experiment will serve the measure the half-
life fluorescence of the cyclical eGFP protein at 37.0°C during protein expression and 
forced thermal degradation studies.   
A chaotropic agent is effective a destabilizing the hydrogen bonding that 
facilitates a protein’s native folding state.  Urea and Guanidinium HCl (GuHCl) are 
two common chemicals that are effective in disrupting the hydrophobic interactions 
of a protein.  Protein stability can be measured by incubation of a fluorescent reporter 
system with GuHCl.  Using real-time monitoring, the kinetic rate of unfolding, 
modeled by first-order decay kinetics can be measured.  Chirico, et al., studied the 
unfolding of eGFP in various GuHCl concentrations and calculated the first-order rate 
constant at 5.0M (0.065 min-1), 3.5M (0.0039 min-1), and 1.5M (0.0075 min-1).  
Moreover, his experiment determined it would take between 50-100 minutes to fully 
denature eGFP at 2.5M GuHCl  [185].  Whereas, Jung et al., expressed cyclized 
eGFP in a PI-PfuI, naturally split-intein, and determined the fluorescence half-life to 
be ~24 hours at 7M GuHCl with a rate constant of 0.008 min-1 at 2.5M GuHCl [186].   
Digestion of C-terminal amino acids are a technique often utilized for amino 
acid sequencing of proteins.  Three carboxypeptidases, A, B, and Y, can be utilized 
based on their specificity for a certain amino acid.  Carboxypeptidase-A 
(aromatic/aliphatic) have higher activity for aromatic or branched amino acids.  Zn2+ 
is a required co-factor and the digestion of arginine (Arg, R), lysine (Lys, K), and 
proline (Pro, P) is slow and sometimes completely inhibited [187, 188].  
Carboxypeptidase-B has specific activity for the digestion of Arg/Lys [189], while 




acid sequence of a protein, a specific exopeptidase can be employed to better interpret 
the degradation patters of enzymatic digestion.  The degradation patterns can be 
measured using mass spectrometry and the amino acid sequence can be predicted.  
The sequential cleavage activity of Carboxypeptidase-A, coupled with the slow rate 
of digestion of Arg, Lys, Pro amino acids, create a robust experiment to study the C-
terminal digestion of a linear and cyclic protein.   
 
3.3 Materials and Methods 
 
3.3.1 GuHCl Degradation of SEC Column Elution Fractions 
 
Expressed proteins, purified by SEC column chromatography, as described in 2.3.4, 
were analyzed for protein concentration using a Bradford Assay and adjusted to 
10µM.  10µL of the protein solution was added to a 96-well clear-bottom, black plate.  
Using the robotic dispensing pumps on the Biotek Neo2 plate reader, 5.0M, 3.0M, or 
1.5M GuHCl was added to the protein solution using a volumetric ratio of 6M GuHCl 
and water, for a total reaction solution volume of 200µL.  The eGFP fluorescence was 
immediately measured using a bottom-read, 485 excitation/516 emission filter. 
 
3.3.2. Carboxypeptidase-A digestion of SEC Column Elution Fractions 
 
The SEC column mobile phase was modified to 25mM Tris, 500mM NaCl, pH 7.5 as 
described in Section 2.3.4 for optimal activity of the enzyme.  Protein solution was 
mixed 1:100 (w/w) with Carboxypeptidase-A with 1mM ZnCl2 and incubated at 
20°C.  After 24 hours, a fraction was quenched with 1mM PMSF and stored at 4°C.  






3.3.3 MALDI-TOF Analysis of Protein Samples 
Samples were desalted using a C-18 ZipTip (EMD Millipore) and eluted using 30% 
ACN/ultrapure water.  2µL of 10g/L Sinapinic Acid was overlaid on the sample 
target and vacuum dried.  2µL desalted sample was overlaid on the dried Sinapinic 
Acid.  2µL of 10g/L Sinapinic Acid was overlaid on the dried sample and vacuum 
dried.  Samples were analyzed using a Bruker Pariflex MALDI-TOF in the linear 
positive mode at a laser frequency of 60Hz within a mass range of 15 000 – 75 000 
kDa and 1000 shots.  The spectrophotometer had a PIE delay of 100ns using an Ion 
source voltage of 20kV/18.3kV, lens voltage 9V, and a linear detection voltage of 
2.698 kV, and a sample rate of 1 ns. 
 
3.4 Experimental Design 
 
This study contains two sets of experiments, designed to measure the stability 
of cyclized (C)TATeGFP under protein denaturing conditions, and to determine the 
transduction efficiency of the cyclized protein.  The first set of experiments were 
performed to interrogate a protein’s stability under chemical, thermal, and enzymatic 
conditions that would typically induced protein degradation or unfolding.  The second 
experiment measured the relative stability of the cyclized protein during protein 
expression.   
Protein stability during production and purification is critical.  Optimal 
conditions for protein stability are empirically determined and measured against 
overall process yields.  During a clinical or commercial manufacturing process, there 




execute a critical processing step without the potential for protein loss or yield.  
Operating temperature of vessels [191], induction and harvest time [192], and pH 
titration targets require operating ranges [193].  The vessel of a bioreactor will 
experience temperature fluctuations from temperature gradients existing between the 
vessel jacket and the culture media.  A key process development study for a clinical 
manufacturing process would be to operate a bioreactor process at varying 
temperature ranges to determine the optimal temperature range.  During empirical 
studies of protein yield over induction time, a maximum will be observed.  However, 
it is not feasible to ensure the manufacturing process will accurately initiate and 
complete the induction during this time.  Therefore, process development studies will 
determine an optimal timeframe for induction time to maximize protein yield.   
3.4.1 Single cell fluorescence stability during protein expression 
 
Protein expression can be monitored by online fluorescence monitoring using 
a plate reader capable of maintaining agitation and temperature set-points.  Three 
eGFP constructs were utilized during this experiment: eGFP (Appendix A.3), 
TATeGFP (Appendix A.8) and (C)TATeGFP (Appendix A.9) were induced with 
four half-log varying concentrations of IPTG: 0.3, 0.1, 0.03, and 0.01mM in a 96-well 
plate (n=5).  The plate was incubated at 37.0°C and agitated at 205 centimeters per 
minute (cpm) in a Biotek Neo2 plate reader.  Every 10 minutes, fluorescence was 
measured using a eGFP—filter (485nm excitation, 516nm emission) and optical 
density (A600).  The resulting curve was analyzed to determine the time-dependent 
stability of eGFP fluorescence.  Cells entering the stationary phase of the growth 




cells entering the death phase, develop porous membranes that permit the 
extracellular mobility of expressed proteins—often into buffer matrices that could 
induce protein instability [196].  Moreover, internal proteases are often deployed by 
E. coli when the growth environment becomes nutrient limited [197, 198].  The 
fluorescence will be continually monitored as protein degradation is observed, 
confirmed by a depressed fluorescent signal. 
Two competing rate equations model the relative fluorescence of the observed 
culture, the rate at which eGFP is synthesized and folded into a native state [F] and 
the rate at which the native state is degraded [Fd].  When Equation 11 is at steady 
state, the rate of synthesis of native-folded eGFP is in equilibrium with the rate at 
which native-folded eGFP is degraded to a non-fluorescent structure.  These two rate 
equations can be combined to find the rate of change of fluorescence in Equation 12. 
.Ö
.)
= ä({ − ä.{.   Equation 11 
kn ~ native folding state constant for eGFP, 0.45 h [199], 




= åçé88   Equation 12 
By combining Equation 11 and Equation 12, fluorescence is a function of optical 
density, and can be analyzed as the relative fluorescence of an E. coli cell that has 






   Equation 13 
When the rate at which eGFP is synthesized, and folded into a native state is in 




fluorescence is at equilibrium, Fss.  Therefore, a plot of F as a function of A600 will 




Since different heterologous proteins will be synthesized at a specific rate, a 
comparative metric can be introduced to correlate the specific activity of a cell in 
synthesizing a native-state eGFP.  This is a very simplified model, only modeling the 
specific fluorescence activity of the cells and the optical density.  From this simplified 
model, it can be correlated to the rate at which the promoter functions to process gene 
expression from the plasmid sequence.  Assume the rate of protein degradation 
approaches zero (Fd=0), eGFP synthesis (both native and unfolded) is the difference 
in promoter activity (P) and the rate at which unfolded eGFP matures from the 





= " − ä(ê − åê   Equation 14 
We combine Equation 14 and Equation 11 at steady state for rate of [native-folded] 
protein synthesis: 
 
" = {nnå ∗ (1 +
è
&[
)   Equation 15 
The rate of protein synthesis can be modulated by the IPTG concentration and 





    Equation 16, 
K ~ [IPTG]P=0.5Pmax 
 
 
In this dissertation, the primary model for protein degradation is first-order 




Equation 17.  Leveau, et al., have published one of the only attempts to fully model 
fluorescence synthesis and degradation using one rate expression, using Michaelis-
Menten kinetics.  This experiment will show the complexity of fluorescence emission 
during protein expression and the proposed, simplified model can be improved.   Data 
collected was modeled using first-order kinetics, and to compare data described in 
[200], a Michaelis-Menten kinetic model of decay will also be calculated to 









   Equation 18, 
KFd ~ (N+F)Fd=Fdmax 
 
 
In this experiment, four different concentrations of IPTG were used to express three 
different eGFP variants: eGFP, TATeGFP and (C)TATeGFP.  The relative 
fluorescence and optical density was measured in real-time and the output was used 
to calculate the degradation rate of the two linear proteins in comparison to the 
cyclized protein.   
3.4.2 Forced degradation studies using SEC purified proteins 
 
Purified proteins will experience thermal, enzymatic, and chemical 
degradation conditions during a manufacturing process.  The three purified eGFP 
constructs were interrogated by three conditions that could induce protein 
degradation.  First, proteins were incubated in a chaotropic agent.  The destabilization 




manipulate biophysical properties as the protein changes is conformational shape 
[201].  The purified proteins were diluted 10-fold (10µL protein to 90µL chaotropic 
agent) in Guanidinium chloride (GuHCl) over three different final concentrations: 
5.0M, 3.0M, and 1.0M.  Since the fluorescence depression is rapid, the Biotek plate 
reader has the capacity for a robotic pump to automatically dispense the GuHCl into a 
96-well plate containing the purified protein.  The delay in the dispense of GuHCl 
and the first read of fluorescence (485nm excitation, 516nm emission) is 0.3s.  The 
fluorescence was every 0.2s thereafter.   
 
3.4.3 Exopeptidase digestion of cyclized eGFP 
 
Exopeptidases that digest the C-terminal amino acid of a protein can be 
monitored using a MALDI-TOF mass spectrometer.  However, for cyclized proteins 
lacking a C-terminal amino acid, a carboxypeptidase would be inactive.  After 
purification of the (C)TATeGFP protein using size exclusion chromatography (3.3.4), 
fractions with an enhanced unprocessed, full translated/transcribed intein sequence 
will be spiked into the fraction containing an enhanced cyclized TATeGFP protein 
solution.  The gel filtration will be purified at pH 6.5 in 50mM Tris, 150mM NaCl, 
optimal conditions for Carboxypeptidase-A.  After 24, and 72-hours the sample will 
be analyzed using a MALDI-TOF mass spectrophotometer to observe any molecular 
weight dispersions.  In this study, CpA was utilized based on its specific activity for 
the six, C-terminal amino acids of the unprocessed intein fragment (six histidine 
residues) and the two, C-terminal amino acids of the translated EcoRI restriction 




acid at the N-1 position of these two sequences is proline which should be slowly 
digested or completely inhibited by CpA.  CpA has a molecular weight relatively 
close to the eGFP-Cintein fragment and therefore the full, unprocessed intein was the 
reference linear protein, susceptible to exopeptidase digestion.  Proline is the N-6 
amino acid of the unprocessed intein and the N-3 amino acid of eGFP (EcoRI is the 
flanking restriction enzyme of eGFP and Nintein).  The digestion of proline would be 
slow or completely inhibited allowing for the molecular weight difference to be 
observed using MALDI.  Using CpY would generate a spectrum of degraded 
products requiring complex analysis due to its universal amino acid enzymatic 
activity.  The hypothesis of this experiment was the full, unprocessed intein would be 
digested through the C-terminal 6His tag and the digestion activity would be halted.  
For (C)eGFP, digestion activity would be completely inhibited.  To measure the 





   Equation 19 
The average molecular weight of the proteins was calculated by the NIST Mass and 
Fragment Calculator.  From an input of amino acid sequence, the program takes the 
average mass incorporating three m/z ion charge states (1+, 2+, 3+) [202]. 
3.5 Results and Discussion 
 
 This experiment used a series of fluorometric reporters to confirm intein-
based protein expression models offer enhanced protein stability.  The four reporters 




exposed to conditions that typically induce protein degradation, monitored by on-line 
fluorescence. 
 
3.5.1. In vitro fluorescence stability 
 
Induction phase fluorescence emission by eGFP, TATeGFP, and 
(C)TATeGFP by online and real-time measurement provided empirical models of 
enhanced in vitro stability of cyclized proteins.  From an industrial biotechnology 
perspective, the harvest time is a critical decision.  Executing a harvest early results in 
low product yield, whereas a late harvest could yield proteins with a sub-population 
that are degraded.  In vitro models in this experiment were conducted using a plate 
reader capable of maintaining fermentation conditions.  Induced cultures could be 
agitated, incubated, and fluorescence monitored in real-time. 
Online fluorescence monitoring of eGFP expression over time produces a 
parabolic curve.  The three different eGFP variants, expressed using five different 
IPTG concentrations exhibited differences in the relative fluorescence.  In Error! 
eference source not found., the fluorescence curves indicate a maximum with a 
relatively stable period of time before and after.  This period of stability at the 
maximum is protein folding equilibrium as the rate of protein expression levels begin 
to decrease alongside an increase in protein degradation rate.  The maximum 
fluorescence measured for all curves, Fmax from Equation 21, was measured on 
TATeGFP [0.1mM IPTG] at 1010 minutes, post induction.  There are two sub-
populations for the fluorescence curves: 0.3mM and 0.1mM IPTG appear to have 




0.01mM, and the un-induced culture have lower, but relatively similar expression 
rates based on fluorescence.  It is typical to observe background expression of 
proteins under a T7 promoter [203, 204].  Expression of the proteins described in this 
work do not appear toxic to the host E. coli strain, therefore the background 
expression was not investigated.  To normalize fluorescence of the three-different 
native-folded proteins, the relative fluorescence was calculated.  This allowed for 
slight differences of induction optical density and the specific colony chosen for 
protein expression.  The specific activity of the cells synthesizing native-folded eGFP 
will also be discussed later. 
The duration of equilibrium and the rate of protein degradation are two key 
factors in protein stability during the induction phase.    A period of equilibrium will 
have a zero slope.  A protein degradation curve can be modeled by linear or 
exponential decay models.  To accurately calculate the relative fluorescence stability 
of the constructs used in these experiments, the instantaneous rate of fluorescence 




    Equation 20 
 
Relative	Fluorescence = 	F) =
ÖØ∞±\J,±dà\~
≤≥¥µØ∞±∂µ/±dà∂≥

















Figure 14. Relative Fluorescence during induction of eGFP, TATeGFP, and 
(C)TATeGFP using 2-log variance of IPTG over time (hours.)  Fluorescence 
(arbitrary units) was measured over time (hours) for different eGFP protein 
constructs.  Five independent inductions were performed for each protein, with 













































Figure 15:  Equilibrium folding and onset of in vitro fluorescence degradation 
during protein expression of eGFP, TATeGFP, and (C)TATeGFP.  The 
instantaneous rate of fluorescence was calculated for eGFP, TATeGFP and 
(C)TATeGFP over time after a maximum was observed in Figure 14.  Five 




























































































3.5.1.1 Fluorescence Equilibrium of protein expression and protein degradation 
 
To further quantitate the duration of fluorescence equilibrium in vitro during 
the induction phase, a quadratic modeling can be utilized.  Performing regression 
analysis on five hours before and after the maxima of fluorescence, a quadratic 
equation can model the fluorescence curve, Equation 22, and when the derivative of 
this curve is at a minimum, the fluorescence is at equilibrium, Equation 23:  
 
{) = ç7; + ∏7 + !   [Equation 22] 
{)π 2ç7 + ∏ ≤ 0.0001    [Equation 23] 
CC+*n = {' − h' ;'N) 				 [Equation 24] 




    [Equation 25] 
 
The equilibrium curves for each condition were modeled using regression analysis.  
The constants in Equation 22 were calculated by minimizing the residual sum of 
squares as in Equation 25.  Table 5 also references the coefficient of variation to 
confirm the regression analysis.  Then, taking the derivative of the second-order 
polynomial and finding the minimum, the boundary of equilibrium could be 
calculated from Equation 23. In Figure 16, there is an enhancement of the 
equilibrium time in the (C)TATeGFP curves.  The calculated equilibrium time for 
eGFP and TATeGFP are similar, yet lower than the cyclized TATeGFP expressed 
using the intein system.  Therefore, the cyclized protein was at equilibrium for a 








 [mM] IPTG A B C R2 
eGFP [0.3] -9.48E-07 9.69E-04 7.30E-01 0.991 
eGFP [0.1] -8.64E-07 8.61E-04 6.57E-01 0.967 
eGFP [0.03] -1.03E-06 1.08E-03 6.81E-01 0.992 
eGFP [0.01] -7.45E-07 7.43E-04 4.58E-01 0.982 
eGFP [-cont] -1.14E-06 1.25E-03 5.94E-01 0.992 
TATeGFP [0.3] -1.23E-06 1.31E-03 6.46E-01 0.936 
TATeGFP [0.1] -1.31E-06 1.39E-03 3.88E-01 0.986 
TATeGFP [0.03] -1.00E-06 1.05E-03 3.92E-01 0.968 
TATeGFP [0.01] -6.64E-07 6.75E-04 4.63E-01 0.988 
TATeGFP [-cont] -1.45E-06 1.45E-03 3.90E-01 0.976 
(C)TATeGFP [0.3] -1.45E-06 1.52E-03 4.13E-01 0.941 
(C)TATeGFP [0.1] -1.47E-06 1.54E-03 4.19E-01 0.957 
(C)TATeGFP [0.03] -1.38E-06 1.46E-03 3.01E-01 0.977 
(C)TATeGFP [0.01] -7.74E-07 8.38E-04 3.78E-01 0.964 
(C)TATeGFP [-cont] 2.47E-08 -3.59E-05 1.94E-01 0.976 
PBS 2.47E-08 -3.59E-05 1.94E-01 0.868 
Table 5: Quadratic approximation constants of fluorescence emission of eGFP, 
TATeGFP, and (C)TATeGFP within 5 hours of fluorescence maximum.  Four 
different concentrations of IPTG [mM] were executed alongside a [-cont] that was not 
induced with IPTG.  The quadratic constants from Equation 22 were analyzed for 





Figure 16:  In vitro fluorescence equilibrium of eGFP, TATeGFP, and 
(C)TATeGFP.  The fluorescence equilibrium time, from Equation 23, can 
quantify the relative stability of the expressed protein, in vitro, during protein 

















































3.5.1.2 Modeling protein in vitro protein degradation using Michaelis-Menten 
kinetics 
 
 The calculated specific growth rate of each E. coli variant harboring a 
different genetic construct should be relatively equivalent.  This hypothesis is 
confirmed in Table 6 as all specific growth rates are within two standard deviations. 
Then the RFU as a function of A600 begins to show relative differences of each eGFP 
variant. The rate of native-folded fluorescence is modeled in Figure 17.  Since eGFP 
is the fluorometric reporter, it is expected that using eGFP as a fusion protein could 
alter the amount of time the protein is synthesized and then folds into the native state.  
This is readily observed by the Hill Equation plot in Figure 18.  Expression of the 
eGFP protein alongside the TAT peptide and the intein-based expression system 
reduces the rate of synthesis of native-folded eGFP. 
From Figure 17, three distinct phases can be observed during protein 
expression: first, there is a rapid increase of fluorescence as the cells remain in an 
active state.  After the fluorescence reaches a maximum, the rate of fluorescence 
degradation is slow.  The optical density remains unchanged whereas the fluorescence 
decreases linearly.  When the cells enter the death phase, marked by a decrease in 
optical density, the fluorescence rate rapidly increases.  The cells internal proteases 
become active and digest the native-folded eGFP at a faster rate than the cells 
synthesize native-folded eGFP.  The rate of native-folded fluorescence has 
approached zero.  
The kinetic rate of fluorescence degradation did not model Michaelis-Menten 




degradation, kdF.  The data supporting the promoter activity were in-line with 
previous published results in  [200]: the Hill constant (h) from Table 6 was 0.9, 1.8, 
and 1.9 for eGFP, TATeGFP, and (C)TATeGFP respectively.  The published results 
from [200] were between 1.5-2.0.  However, as observed in Figure 19, a multi-factor 
expression would be required to fit the curve.  The data presented in this section does 
not yield a single curve.  The slope of Figure 17 does not yield a single-straight line, 
but two distinct phases.   
The specific activity of the cells in synthesizing native-folded GFP and the 
onset of fluorescence degradation should be modeled independently.  The originally 
proposed model from Leveau, et al., does not account for the additional two phases 
that are observed in Figure 17.  These two phases, existing after the cells are 
harboring a positive specific growth rate, do not follow a single-rate expression 
model, such as Michaelis-Menten kinetics.  The Hill equation is generally applied to 
model the rate at which a gene is regulated by transcription factors.  However, the 
data presented in this section supports that protein degradation occurs when the 
specific growth rate of the cells is negative, indicating decay.  Thus, the specific 









Figure 17 Relative Fluorescent Units as a function of optical density of eGFP 
variants after induction.  Four concentrations of IPTG were used to induce 
expression of (C)TATeGFP, TATeGFP, and eGFP proteins.  In a plot of RFU as a 
function of A600, three distinct phases can be observed: the first is an accumulation of 
fluorescence as the cells are actively transcribing protein and it folds into a native-
state, the second is when the cells enter a stationary phase and the activity of the 
promoter decreases, and the third phase is the cells enter the death phase and the rate 










































Figure 18.  Modulation of single cell fluorescent protein synthesis as a function of 
IPTG concentration.  The rate of protein synthesis, modeled by a fluorometric 

























































 [IPTG] A600(t) Slope F(A600) 
Slope P Pmax K h 














0.3 1.25 0.44 1578 1.98 
1.245 0.015 0.910 
0.1 1.11 0.16 1381 
 
1.53 
0.03 1.25 0.49 1267 
 
1.58 
0.01 1.13 0.38 810 
 
0.91 








0.3 0.91 0.36 1297 
 
1.18 
0.512 0.015 1.800 
0.1 1.07 0.13 1152 
 
1.22 
0.03 0.84 0.20 965 
 
0.81 
0.01 1.02 0.35 812 
 
0.82 










0.3 1.02 0.22 997 
 
1.01 
0.522 0.027 1.900 
0.1 0.92 0.32 826 
 
0.76 
0.03 1.01 0.43 759 
 
0.77 
0.01 0.93 0.41 667 
 
0.61 
0 0.87 0.41 563 
 
0.49 
Table 6 Protein synthesis metrics as a function of RFU, A600, and IPTG 
concentration.  Fluorescence and optical density curves were examined to calculate 
the single cell fluorescence of eGFP, TATeGFP, and (C)TATeGFP.  Using a 2-log 
range of IPTG concentrations, the relative protein synthesis activity of a cell is 








Figure 19 Michaelis-Menten 
Kinetic Model of [0.3mM 
IPTG] eGFP, TATeGFP, and 
(C)TATeGFP during 
fluorescence degradation.  
After the maximum, the 
degradation pattern is complex 
and Michaelis-Menten kinetic 
model does not converge for the 
data.  It is expected the plot 
would produce a straight line.  
The experimental half-life 
fluorescence is the enlarged 







































3.5.1.3 Modeling in vitro protein degradation using first order decay kinetics  
 
Upon fluorescence degradation, mathematical modeling can extrapolate an 
estimated fluorescence half-life for the eGFP, TATeGFP, and (C)TATeGFP 
constructs during protein expression.  The half-life of fluorescence during protein 
expression can determine the relative stability of the protein when exposed to possible 
chemical, thermal, and enzymatic degradation conditions.  These conditions can be 
induced when the protein is expressed intracellularly, or upon the cell death phase, 
and the creation of a porous membrane, extracellular degradation.  Upon observation, 
the degradation of fluorescence emission does not follow a standard first-order kinetic 
decay.  A semi-log plot vs. time of the fluorescence after the maxima does not form a 
straight line as a first-order reaction should, as observed in Figure 20.  The three 
eGFP variants, expressed at 0.1mM IPTG exhibit slow decay and then a rapid 
decrease.  Therefore, the modified kinetic decay model for fluorescence incorporates 
a parabolic function for the decay constant, At2 + Bt + C. 
{) = {2,ë56&Ä)     Equation 26, 




    Equation 27 
 
The degradation rate can be modeled by exponential regression and decay 
kinetics.  The residual sum of squares in Equation 23 was minimized while 




Equation 27.  The number of empirical half-life calculations were limited based on 
the duration of the experiment. 
 
All four IPTG concentrations of the (C)TATeGFP model extended 
fluorescence half-life when compared to compared to the TATeGFP and eGFP 
models.  However, there also appears to be increased half-life fluorescence as the 
IPTG concentration increases.  When comparing the half-life of the (C)TATeGFP 
models, the half-life is at a maximum using 0.3mM IPTG and a minimum using the 
lowest concentration of 0.01mM.  For the non-cyclized protein models, there is no 
correlation between half-life fluorescence and IPTG concentration.  
The relative fluorescence of the (C)TATeGFP constructs were relatively 
lower than that wild type eGFP and TATeGFP constructs.  This is expected as the 
intein processing is a kinetic reaction and some of the intein processing occurs ex 
vivo.  The data correlates relatively well with previous published results of eGFP 
fluorescence degradation during protein expression, 2.6 hours for half-life.  The 
average half-life of eGFP over the four IPTG concentrations was 3.56 ± 0.26 hours.  
 The parabolic rate law proposed in this experiment is an empirical model with 
no fundamental underlying mechanism.  This law was proposed to allow for a single 
exponential function to fit the complex degradation patterns of native-eGFP 
fluorescence during protein induction.  The Michaelis-Menten kinetic fitting 
supported a new hypothesis that fluorescence degradation is complex.  Modeling the 
degradation using a single-parameter expression or first-order kinetics does not 







Figure 20.  Semi-logarithmic 
plot of Fluorescence as a 
function of time for 
(C)TATeGFP [0.3mM] after 
Fluorescence Maximum.  
After the maximum 
fluorescence, the decay in 
fluorescence does not follow a 
first-order kinetic model with a 
single-constant, exponential 
decay model.  This model 
suggests the decay constant is a 

















































eGFP	 -5.6E-07	 -1.5E-03	 1.3E-01	
TATeGFP	 -3.4E-06	 1.7E-04	 -1.2E-02	




eGFP	 -6.3E-06	 7.6E-04	 -2.6E-02	
TATeGFP	 -2.1E-06	 6.5E-05	 2.0E-02	




eGFP	 -3.1E-06	 -1.7E-05	 1.1E-02	
TATeGFP	 -1.3E-06	 -1.5E-03	 1.1E-01	




eGFP	 -3.9E-06	 9.4E-05	 -1.4E-03	
TATeGFP	 -3.2E-06	 1.6E-04	 -1.2E-03	
(C)TATeGFP	 -3.3E-06	 5.0E-04	 -1.8E-02	
 
Table 7: Exponential coeficients of eGFP, TATeGFP, and (C)TATeGFP by 
regression analysis, during in vitro fluorescence degradation.  The regression 
coeficients were determined to estimate the fluorescence half-life of the constructs 
using four different concentrations of IPTG during induction: 0.01, 0.03, 0.1, and 
0.3mM.  The results shown are are the average of five replicates with one standard 




























eGFP	 225	±	51.8	 232	±	4.51	 195	±	36.0	 232	±	4.51	
TATeGFP	 235	±	30.8	 237	±	5.24	 295	±	20.6	 298	±	4.51	











eGFP	 230	±	49.1	 235	±	4.24	 210	±	33.5	 217	±	4.11	
TATeGFP	 200	±	41.4	 203	±	3.06	 245	±	57.3	 247	±	2.59	
(C)TATeGFP	 305	±	81.5	 304	±	3.65	 275	±	53.3	 267	±	2.59	
 
Table 8. In vitro half-life fluorescence (minutes) of eGFP, TATeGFP, and 
(C)TATeGFP, induced at half-log IPTG concentrations (0.01, 0.03, 0.1, and 
0.3mM), based on exponential regression kinetics.  After induction, eGFP was 
monitored by online fluorescence (485ex, 516em) every 10 minutes.  After 
culmination of the stationary phase, the fluorescence reached a maximum for all 
conditions.  Therafter an expontential decrease in fluorescence was modeled using 
regression analysis.  For the experimental data, the results shown are are the average 
of five replicates with one standard deviation.  For the regression data, the half-life 





3.5.2 Fluorescence half-life under induced chemical degradation conditions 
	
Exposing a protein to a chaotropic agent results in protein unfolding and a 
rapid, forced degradation study.  The intein-fusion proteins in this experiment, 
(C)TATeGFP and (C)eGFP, exhibit enhanced fluorescent stability under chaotropic 
agents.  From Figure 21, GuHCl induced rapid decay of fluorescence at 5.0M, 
whereas the intein-fusions required the duration of the experiment (20 minutes) for 
fluorescent decay.  A decrease in GuHCl resulted in an increase fluorescent stability 
from all four models.  The (C)eGFP models retained >50% fluorescence during the 
experiment, whereas the linear models (eGFP and TATeGFP) had complete decay 
within 15 minutes.  All conditions modeled equal stability under the lowest GuHCl 
concentration of 1.0M. 
 The regression modeling of the decay kinetics correlates to experimental data.  
For conditions where a half-life can be experimentally determined, the regression 
modeling half-life calculation compares.  In Equation 26, three variables are 
determined by regression analysis: the initial fluorescence [Fi], first-order rate 
constant [kd], and an offset factor [C].  The offset factor is included in the case a 
chaotropic concentration does not completely denature the protein.  When assessing 
the model validity, the half-life, calculated from the first-order rate-constant 
extrapolates to similar experimental half-life empirical values for all 5.0M GuHCl 
conditions, and the two linear eGFP motifs for 3.0M GuHCl.  The initial 
fluorescence, from regression analysis should model the normalized initial 




initial fluorescence approaching unity.  Since all models used a relative fluorescence 
where Ft = F*Fi-1, a regression model should have an Fi ~ 1.0. 
 The chemical degradation of eGFP variants in this experiment demonstrate the 
enhanced stability of an intein-based, cyclized protein. Two (C)eGFP proteins were 
tested in this experiment alongside their wild-type counterpart, and in the 3.0M and 
5.0M conditions, the intein-based proteins exhibited enhanced fluorescence half-life.  
Since the intein-based proteins have a covalent bond that forms between the N-
terminal and C-terminal amino acids, the backbone appears to be more resistant to 
destabilization of hydrogen bonding and maturation of the proper folding 
conformation for protein functionality.  Since eGFP fluorescence is an excellent 
reporter for backbone stability and maturation of the proper folding, it can be deduced 
that a longer fluorescence half-life, under chaotropic conditions, results from protein 















































eGFP		 	 	 (C)eGFP	 	 	 	
	 	 	
TATeGFP		 	 (C)TATeGFP 
Figure 21.  Forced chemical degradation from GuHCl on purified gfp, 
(C)eGFP, TATeGFP, and (C)TATeGFP from a chaotropic solution.  Purified 
gfp variants were exposed to chaotropic conditions and the fluorescence was 
monitored in real-time.  Unfolding of proteins could be monitored by the 




 5.0M GuHCl 3.0M GuHCl 
Fi ± s kd   
 [min-1] 
Fi ± s kd  
[min-1] 
eGFP 0.951 ± 3.72E-02 2.98 1.06 ± 3.85E-02 0.207 
TATeGFP 0.958 ± 3.18E-02 3.10 1.08 ± 3.42E-02 0.200 
(C)eGFP 0.958 ± 5.72E-02 0.105 0.92 ± 1.46E-02 2.52E-03 
(C)TATeG
FP 
0.958 ± 7.45E-02 7.00E-02 0.91 ± 2.14E-02 5.34E-03 
 1.5M GuHCl 
Fi ± s kd  
[min-1] 
eGFP 0.940 ± 2.67E-02 5.88E-03 
TATeGFP 0.945 ± 6.09E-03 5.38E-03 
(C)eGFP 0.946 ± 1.13E-02 2.77E-03 
(C)TATeG
FP 
0.936 ± 1.74E-02 4.81E-03 
Figure 22. Exponential coeficients of eGFP, TATeGFP, (C)eGFP, and 
(C)TATeGFP by regression analysis, from forced chemical degredation by 
GuHCl.  The regression coeficients [Fi, kd] were calculated from Equation 25 and 
Equation 27.  The results shown are are the average of three replicates with one 

































[min ± s] 
Experimental 
[min] 
Regression     
[min ± s] 
eGFP <0.35 0.232 ± 0.03 4.20-4.55 3.35 ± 0.03 
TATeGFP <0.35 0.223 ± 0.03 4.20-4.55 3.47 ± 0.04 
(C)eGFP 8.40-8.75 6.63 ± 0.52 N/A 274 ± 2.11 
(C)TATeGFP 13.65-14.00 9.90 ± 0.74 N/A 129 ± 1.46 




[min ± s] 
  
eGFP N/A 117 ± 2.68   
TATeGFP N/A 128 ± 6.07   
(C)eGFP N/A 249 ± 1.13   
(C)TATeGFP N/A 144 ± 1.74   
Figure 23. Fluorescence half-life (minutes) of eGFP variants under induced 
chemical degradation.  Four variants of eGFP were exposed to high concentrations 
of GuHCl to destabilitize hydrogen bonding and induce a depression in fluorescence, 
regression half-life fluorescence listed in minutes. The results shown are the average 























3.5.4. Fluorescence half-life under induced thermal degradation conditions 
 
 Thermal degradation studies are often executed above normal operating 
conditions of a protein.  For a protein therapeutic, the majority of the residence time 
is occupied in a frozen vial, awaiting administration to a patient.  Therefore, a 
stability study at 37.0°C will be an accelerated stability study.  In this study, the 
accelerated temperature stability study did not reveal a significant enhancement of the 
(C)TATeGFP as shown in Table 10.  The experimental setup for this study was not 
executed long enough to determine an experimental half-life as the protein solution 
experienced evaporation of the PBS matrix over the 16-hour duration of the 
experiment.  Using the regression analysis methods described in 3.5.1.3, the 
regression fluorescence half-life was calculated.  Wild-type eGFP exhibited the 
highest fluorescence half-life. TATeGFP, alongside (C)eGFP and (C)TATeGFP had 
regression-derived fluorescent half-life within 1-standard deviation.   
 Reported fluorescent half-life of wild-type eGFP is a broad range, from 24-26 
hours at 37.0°C [184, 205], to 2.8 hours in vitro expression using fibroblast cells 
[183], 4.5-6.1.  It is possible the thermal stability enhancement of (C)TATeGFP could 
occur at higher temperatures or could be empirically observed during a longer-
duration experiment.  Theoretically, enhanced stabilization of the hydrogen bonding 
in eGFP that is created using intein-based proteins should provide enhanced thermal 
stability.  This theoretical prediction was confirmed when measuring fluorescence 















Table 9. Exponential decay kinetic constants of induction of thermal degradation 







Table 10. Fluorescence half-life (minutes) of eGFP variants under induced 
thermal degradation.  Four variants of eGFP were exposed to 37.0°C for 16 hours to 
induce degradation from temperature induced fluorescence degradation.  The 
regression analysis (listed in minutes) does not appear to show any significant 
enhancement from the cyclized Intein proteins.  The results shown are are the average 





















3.5.5 Enzymatic Degradation of (C)eGFP 
 
 One of the unique features of the intein-based, cyclized protein expression 
system, is the synthesized protein’s covalent bond between the N-terminal and C-
terminal amino acid.  In this study, a carboxypeptidase was used to measure the 
activity of C-terminal amino acid digestion.  The hypothesis was that a linear protein 
would be subjected to C-terminal amino acid digestion, whereas a cyclized protein 
would be protected.  In this experiment, after 24 and 72-hours, the cyclized-eGFP 
protein had no observable degradation.  Whereas, the linear, unprocessed intein had 
multiple degraded artifacts.   
 Using MALDI-TOF analysis, the digested solution was analyzed for proteins 
and a calculated molecular weight could be observed.  After 24 hours, the observed 
peak at the theoretical molecular weight of eGFP remains in-tact.  However, several 
new peaks are observed for the linear, un-processed intein fragment.  Suggesting 
exopeptidase digestion, this confirms the hypothesis of slow CpA digestion.  After 72 
hours, the peak at the theoretical molecular weight of eGFP remains in-tact.  Only 
two predominant peaks are observed for the linear, un-processed intein fragment.  
This experiment confirmed our hypothesis as degradation could be observed after 24 
and 72-hours of the unprocessed intein, whereas the (C)eGFP retained its theoretical 
average mass.  Several degraded isoforms of the unprocessed intein were observed.   
 Using the amino acid sequence of the two proteins, the measured mass of the 
protein fragments can be predicted.  The unprocessed intein and (C)eGFP C-terminal 
amino acid sequences (Figure 24) have several amino acids that are slowly digested 




compared against the measured molecular weight of the MALDI in Table 11.  It 
should be noted the measured and theoretical molecular weight of (C)eGFP for all 
three time points remains constant and accurate.  Moreover, as a control for the assay, 
the measured and theoretical molecular weight of CpA are consistent.  This 
experiment supports the hypothesis that a cyclized protein, absent of a C-terminal 
amino acid, will not be subjected to exopeptidase digestion.   
 
Unprocessed Intein:  LDLITLENIKQTEEALDNHRLDFGTIKHHHHHH-COOH 
 
(C)eGFP:   DPNEKRDHMVLLEFVTAAGITLGMDELYKEF-COOH 
Figure 24 C-terminal amino acids of the (linear) unprocessed intein fragment 
and the transcribed (C)eGFP fragment.  Three enzymes have slow kinetic rates of 








Figure 25. Digestion analysis of cyclic and linear proteins using MALDI-TOF.  A 
protein solution containg a (C)eGFP and the unprocessed intein fragment were 
subjected to 24 and 72-hour digestion of Carboxypeptidase-A.  After incubation, the 
reaction was quenched with PMSF and analyzed using a MALDI-TOF spectrum 
analysis.  The molecular weight of the observed molecular weight peaks is identified 































1 (C)eGFP 27423.04 27415.02 F [N-0] 292.54 
2 Unprocessed Intein 46057.31 46,071.03 H [N-0] 297.80 
3 (C)eGFP 27414.33 27415.02 F [N-0] 25.19 
4 CpA 34815.46 34823.45  229.44 
5 Unprocessed Intein 42990.97 42,955.69 I [N-29] 821.31 
6 Unprocessed Intein 43001.86 42,955.69 E [N-25] 1074.83 
7 Unprocessed Intein 43924.70 43,920.68 L [N-17] 91.53 
8 Unprocessed Intein 44619.77 44,601.57 D [N-11] 408.06 
9 Unprocessed Intein 45207.13 45,209.28 K [N-5] 47.56 
10 (C)eGFP 27418.40 27415.02 F [N-0] 123.29 
11 CpA 34835.78 34823.45  354.07 
12 Unprocessed Intein 42452.05 42,485.12 I [N-29] 778.39 
13 Unprocessed Intein 42990.97 42,955.69 E [N-25] 821.31 
Table 11. Measured and Theoretical Mass Tabulation of MALDI-TOF resolved 
proteins after CpA digestion. After 24 and 72 hours of digestion, proteins were 
subjected to molecular weight analysis using mass spectrometry.  The table calculates 
the relative error (∆ppm) of the theoretical protein identified from the MALDI-TOF 








The practicality of this experiment for transfer into an industrial 
biotechnology manufacturing environment for clinical or commercial products is 
significant.  Without an online and real-time measurement for protein stability, a 
process must rely on a robust process to determine harvest timing of the process.  As 
discussed earlier, this harvest time is a determined range that allows for a period of 
time when the harvest can be initiated.  Enhancing the stability of a protein during 
expression allows for a longer duration of a harvest time.  This could alleviate 
termination of a batch for missing a harvest time. 
	 The accelerated stability study executed in this experiment provided empirical 
evidence that (C)TATeGFP has enhanced fluorescent stability under protein 
degradation conditions.  As a fluorometric reporter, the (C)TATeGFP functioned to 
increase the fluorescent half-life when tested against wild-type TATeGFP and eGFP.  
The direct application of this study would be overall long-term recovery of 
(C)TATeGFP protein solutions under physiological conditions, storage temperatures, 
and protein expression conditions.  Expressing a lead protein candidate as a cyclized 
intein would provide a clinical or commercial manufacturing company developing 
therapeutic proteins desired enhanced stability. 
	 The hypothesis for enhanced thermal and chemical stability of intein-fusion 
proteins, originates from stronger hydrogen bonding in the protein backbone.  If a 




could provide enhanced stability in either region.  The hydrogen bonding in a protein 
backbone provides protection from hydrophobic regions in the protein.  Essential to 
protein structure-function, these hydrophobic regions are critical to a proteins overall 
efficacy. When exposed to high temperatures or chaotropic agents, the rigid structures 
maintain protection of the hydrophobic regions for an enhanced period of time. 
The covalent bond between the N-terminal amino acid and C-terminal amino 
acid in an intein-based expression system provides increased rigidity and protection 
for these hydrophobic regions.  However, it does present limitations of the target 
cyclized protein.  eGFP was selected for this study based on the close proximity of 
the C-terminal and N-terminal amino acids under native-folding conditions.  For more 
complex proteins, such as antibodies, or proteins that do not have neighboring amino 
acids, the intein-based system might express a protein that folds into an inactive 
secondary structure.   
 Another significant enhancement of the intein-based protein expression 
system is a broader manufacturing range for harvest time.  Using the fluorometric 
reporter system, the (C)TATeGFP exhibited a longer equilibrium time when the 
protein expression rate began to decline and the protein degradation rate increased.  
Moreover, when protein degradation was observed in vitro, during protein expression, 
the fluorescence half-life of the (C)TATeGFP was enhanced.  For a clinical or 
commercial manufacturing process, a longer equilibrium or slower protein 
degradation rate is a more robust process.  This will allow for a longer acceptable 





 A novel kinetic rate law for fluorescence degradation was proposed.  This rate 
law allows for a single kinetic expression to model the complex degradation of 
native-folded eGFP during protein expression.  The parabolic rate constant models a 
time-dependent rate constant.  As the protein induction phase progresses, the specific 
growth rate decreases as the rate of native-state fluorescence degradation increases.  
A second contributing factor, incubation temperature, should enhance the degradation 
capacity of the natural proteases.  This empirical rate law served to model a complex 














Chapter 4:  Transduction kinetics and efficiency of a 




CPP-mediated uptake can be rapidly measured by quenching extracellular 
fluorescence with trypan blue.  Trypan blue will penetrate cells with compromised 
membranes that could transduce proteins unmediated. In this study, eGFP is 
expressed alongside the transactivator of transcription (TAT) peptide derived from 
HIV-1 that can function as a cell-penetrating peptide. The TAT-eGFP fusion protein 
is also expressed alongside an artificial split-intein system.  A cyclical protein, 
expressed as a intein-based fusion protein, exhibits enhanced protein stability against 
thermal, chemical, and enzymatic degradation.  The (C)TATeGFP exhibits enhanced 
in vitro stability during protein expression, resistance against exopeptidase digestion, 
and resistance against chaotropic agents.  A cell-penetrating peptide-protein fusion 
can transduce a cell membrane to delivery an intracellular protein with low cytotoxic 
effects.  A cyclical, cell-penetrating, peptide-protein fusion is a novel tool for 
fluorometric reporting studies and a backbone for the delivery of intracellular 
therapeutic proteins with enhanced thermal, enzymatic, and chemical stability. 
This study used an in vitro assay to measure enhanced transduction of a 
cyclical, cell-penetrating, peptide-protein fusion using eGFP and mCherry as 
fluorometric reporters.  HEK293 cells were plated on culture plates and incubated 
alongside 5µm and 2.5µm of fluorometric reporters: eGFP and mCherry, expressed as 
fusion proteins with the TAT peptide and the intein-based system.  Extracellular 




measured using a plate reader.  Trypan blue also functioned as a utility to confirm the 
low cytotoxicity of the compounds tested.  Inclusion of the TAT-peptide in the 
(C)eGFP increased intracellular fluorescence by 75.4 ± 5.14 (5µm) and 74.6 ± 9.72% 
(2.5µm) for the cyclized (C)TATeGFP fusions in comparison to the 43.8 ± 6.37% 
(5µm) and 71.9 ± 9.79% (2.5µm) of the TATeGFP fusion.  Inclusion of the TAT-
peptide in the mCherry Intein increased intracellular fluorescence by 93.5 ± 18.2 
(5µm) and 79.1 ± 15.3% (2.5µm) for the cyclized (C)TATmCherry fusions in 





 Cell-penetrating peptides have the ability to transport molecules through the 
cell membrane, while retaining the function of the transported molecule.  Discussed 
earlier, it is hypothesized that Maternin requires intracellular delivery for inhibition of 
tumor proliferation in carcinoma cell lines.   As a fusion protein to eGFP, Maternin 
did not exhibit efficacy when presented to the outer membrane of KSY-1, HTB-123, 
and PC-3 cancer cell lines.  A TAT peptide-eGFP fusion protein could be a functional 
reporter for intracellular delivery modeling and analysis.  Essential for a functional 
delivery system, the transported molecule’s intracellular function can be modeled by 
a fluorometric reporter.  A TAT-fluorometric reporter fusion protein is an effective 
tool to measure transduction capacity.  In this experiment, the effectiveness of a 
cyclized TAT-fluorometric reporter is tested.  The TAT peptide has been covalently 




in the cytoplasm of live cells [206].  However, this model leaves the transduced eGFP 
protein susceptible to thermal, enzymatic, and chemical degradation.  It has been 
previously discussed, a cyclized TATeGFP fusion offers enhance thermal, chemical, 
and enzymatic stability to the wild-type counterpart.  In this experiment, the first Ssp 
DnaE split-intein derived, fully-cyclized TATeGFP fusion, is tested for transduction 
capacity and intracellular fluorometric reporting. 
 A transduction assay should measure the potential of compounds to traverse 
the outer membrane of live cells.  Using a fluorescent protein as a fluorometric 
reporter, the intracellular fluorescence of a cell is an effective metric from 
transduction capacity.  However, the extracellular fluorescence of the surrounding 
media must not contribute to the signal.  In this experiment, trypan blue is used to 
mute the extracellular fluorescence.  Trypan blue is a multi-functional tool in the 
transduction assay as it will also quench intracellular fluorescence of dead cells that 
could permit transduction of all exogenous proteins.  Endogenous auto-fluorescence 
is expected to contribute to the quenched fluorescent signal.  The purified 
fluorometric reporter proteins will be quenched in PBS to determine the fluorescence 
quenching efficiency of trypan blue.   
 The second phase of the experiment is to measure the in vitro transduction 
capacity of the TAT-fluorometric reporter system.  Actively-cultured cells, co-
incubated with the proteins would be incubated for several days and the cell lysate 
fraction would be probed for fluorescent proteins using western blot analysis.  It is 
common to include a ubiquitous protein, such as actin, to normalize the total lysate 




 Previous experiments have tested the transduction kinetics and capacity of 
TATeGFP fusions.  There has been a widely reported timescale for the maximum 
fluorescence measured of intracellular delivery of TATeGFP: from 15 seconds [207], 
to 30 minutes [208], to 24-hours [209].  Secondly, there has been a widely reported 
time scale for the rate of transduction, expressed as a fluorescent half-life, or the 
amount of time required for half of the maximum fluorescence to be measured: from 
<1 minute [210], to 13.2 minutes for fluorescence half-life [211].  Finally, for in vitro 
transduction capacity of TATeGFP proteins in a cell culture environment, the 
detection of eGFP in the lysate fraction has been identified on an anti-GFP western 
blot after 48 hours [212] and 72 hours [213].  We speculate several factors contribute 
to the broad range of kinetics: purity of the purified protein, unique ORF features, 
expression plasmid and promoter, and execution of the fluorometric assay. 
This experiment is design to measure the rate of transduction of a novel cell-
penetrating peptide-protein fusion, and long-term stability in vitro.    
 
4.3 Materials and Methods 
 
Purified protein samples were expressed and purified as described in 2.3.1, 2.3.2, 
2.3.3, 2.3.4. 
4.3.1 Cellular Transduction Assay 
 
HEK293 cells (Pavlaikis, NCI-Frederick) were cultured in DMEM+2mM L-
Glutamine and 10% FBS, incubated at 37.0°C and 5% CO2.  The cells were plated 
onto a 24-well plate at 5E5 vc/mL in 1.0mL and incubated overnight.  The media was 




containing the target compound was overlaid onto the cells and incubated at 37.0°C 
and 5% CO2.  Extracellular fluorescence was quenched by the addition of 100µL 
0.4% trypan blue and fluorescence was measured using a 485ex/516em filter for 
eGFP and 588ex/609em for mCherry.  Quenching of extracellular fluorescence was 
confirmed by incubating the compounds in PBS and adding 10% (v/v) of 0.4% trypan 
blue and measuring fluorescence. 
 
4.3.2 Western blot analysis of HEK293 lysates 
 
HEK293-F cells (Invitrogen, Irvine, CA) were cultured in serum-free, 293-
Freestyle media in 125mL shake flasks, agitated at 0.55m/s at 37.0°C and 5% CO2.  
5µm of (C)TATeGFP and 5µm of (C)eGFP were added to the shake flask.  24, 48, 
and 72 hours, post-addition, a 5.0mL sample was removed from the culture and 
centrifuged at 200rcf for 10 minutes.  The cell pellet was washed three times with 
PBS, pH = 7.4.  The pellet was lysed with 0.1% TritonX-100 and denatured with 
10U/mL Benzonase (EMD-Millipore, Billerica, MA).  The lysate was centrifuged at 
15,000rcf for 30 minutes.  The resulting supernatant was mixed equally with 2x 
Laemmeli Buffer + bME.  The proteins were separated using a 4-15% Tris-HCl 
gradient, reducing gel and then transferred to a nitrocellulose membrane.  The blot 
was probed with 1/1000 dilution anti-GFP and 1/2000 anti-b-actin (Thermo, 





4.4 Experimental Design 
 
This experiment was designed to measure the transduction kinetics and 
efficiency of cyclical TAT-fusion proteins.  A fluorometric reporter system was 
utilized by expressing the TAT-fusions with eGFP and mCherry.   The cyclic, 
fluorometric reporter proteins were produced using an intein-based expression 
system.  Trypan-blue was used to quench extracellular fluorescence of the reporter 
proteins and quench the intracellular fluorescence of non-viable cells with porous 
membranes.  If the TAT-fusion protein could transduce its fluorometric reporter 
across the cell membrane, then intracellular fluorescence could be measured.  
Expressing the TAT-fusion protein with the intein-based system could measure the 
effect of a cyclized protein on transduction efficiency.  We hypothesized inclusion of 
the TAT-peptide would increase transduction efficiency of a fluorometric reporter, 
expression a fluorometric reporter-TAT fusion using the intein-based system could 
transduce cells, and the fluorometric reporters would retain structure/function and 
fluoresce inside the cell.  It is hypothesized that cells will emit auto-fluorescence and 
the fluorescent quenching efficiency of trypan blue will not be complete.  Therefore, 
proteins were also incubated in PBS to determine the fluorescent quenching 
efficiency of trypan blue.   
 Forced degradation of the cyclized proteins were extensively discussed in 
Chapter 3.  In this experiment, in vitro degradation could be measured by probing the 
lysate fraction of cells for the fluorometric reporter.  Cells that were trypsinized and 
lysed could be probed for eGFP using a primary antibody.  As a control to normalize 




hypothesized that the lysate fraction of cells incubated with a TAT-fusion protein 
could be uniquely identified by an anti-GFP antibody.  Moreover, as the incubation 
time of the TAT-fusion protein increased, degradation of the internalized protein 
could be observed by the relative signal of the lysate fraction using the anti-GFP 
antibody.  
 
4.5 Results and Discussion 
 
4.5.1 Cellular Transduction Assay 
 
 
 The transduction assay used a fluorometric reporter system to measure cell-
penetration of a target compound.  In this experiment, eight compounds were tested: 
two fluorometric reporters (eGFP and mCherry), with and without the TAT peptide as 
a fusion protein, and with and without the intein-based expression system for 
production of cyclized proteins.  Overall, proteins expressed with TAT as a fusion 
protein had higher transduction efficiency than proteins expressed without the cell-
penetrating peptide.  Expressing the fluorometric reporter with the TAT fusion in the 
intein-based system did not affect the transduction capacity of the protein.  Finally, 
the two fluorometric reporters had relatively similar transduction capacity when 
expressed as a fusion protein with the TAT peptide. 
 
 Two concentrations of eGFP fluorometric reporter proteins were tested for 








to normalize the fluorescence signal and compare intra-assay samples.   From Figure 
28, increasing the concentration of the protein two-fold did not increase the 
transduction efficiency two-fold.  Both transduction efficiency measurements were 
within one standard deviation of both measurements.  For the (C)TATeGFP, the 
percent increase of 5µm and 2.5µm for the four time points (15, 30, 60, and 120 
minutes) were 11.5, 14.1, 4.36, and 8.24% respectively.  Whereas for TATeGFP, the 
percent increase of 5µm and 2.5µm for the four time points (15, 30, 60, and 120 
minutes) were 1.39, (1.68), 6.23, and 13.01% respectively.  There does not appear to 
be a dose-dependent effect on transduction efficiency.  The saturation of transduced 
protein could be reached at 2.5µm      
The kinetics of transduction were rapid and the maximum fluorescence was 
measured within 30 minutes of incubation. The sum of squares was minimized to 
calculate the Fmax, and first order exponential rate-constant as described in Equation 
27 and Equation 28.  The half-life (t0.5) calculated from the regression models was < 
6.5 minutes for all four TAT-fusion proteins (Table 11).  The transduction 
experiment was repeated, measuring intracellular fluorescence of (C)TATeGFP and 
(C)eGFP every 2 minutes during incubation.  The (t0.5) calculated was more rapid, 
1.77 minutes for the (C)TATeGFP (Table 11).   
mCherry was used as a fluorometric reporter to determine if the transduction 
kinetics of the TAT cell-penetrating peptide are affected by the fusion partner.  
mCherry (28.8kDa) is of similar size to eGFP (26.7kDa) and forming a beta-barrel 
structure when under native folding conditions.  The TATmCherry fusions both 




was rapid for the cyclized and linear TATmCherry proteins.  From Figure 30, the 
(C)TATmCherry and TATmCherry reached maximum fluorescence within 15 
minutes.  The intracellular fluorescence remained constant over the next 2 hours.  The 
background fluorescence, from the (C)mCherry and mCherry incubated cells, was 
consistent for both proteins and both concentrations.  At 120 minutes, the 
fluorescence of the TAT-peptide proteins decreased and was within one standard 
deviation of the wild-type proteins.  The mCherry protein could have minimal 
cytotoxicity to the cells and this is expressed by the fluorometric assay after 2 hours.   
Two factors could contribute to the background fluorescence of the 
fluorometric assay.  From Figure 31, the fluorescence of the eGFP proteins incubated 
in PBS has a relative fluorescence of approximately 0.2.  Whereas, the mCherry 
proteins have a nearly zero fluorescent signal.  From Figure 28 and Figure 30, the 
wild type eGFP and mCherry proteins, respectively (without the TAT peptide) have a 
relative fluorescent signal of 0.25.  Therefore, it can be assumed the quenching 
efficiency of mCherry is higher than that of eGFP.   
The maximum fluorescence measured of trypan blue quenched HEK293 cells 
incubated with TAT-fusion proteins is higher than that without.  The maximum 
relative fluorescence was determined for all eight proteins incubated alongside the 
adherent HEK293 cells and trypan blue.  From Figure 32, the positive control 
compounds, linear TATeGFP and linear TATmCherry, both exhibited enhanced 
intracellular fluorescence in comparison to the non-TAT counterpart.  The two 
proteins, (C)TATeGFP and (C)TATmcherry, exhibited comparable intracellular 




enhanced intracellular fluorescence greater than one standard deviation of the non-
TAT counterpart.   
The results of this experiment are comparable to previously published results 
of testing TATeGFP proteins.  The previous results utilized a non-cyclized TATeGFP 
and measured the amount of time required for fluorescence half-life between < 1 
minute to 13.2 minutes.  In this experiment, (C)TATeGFP and TATeGFP reached 
maximum fluorescence in less than 6 minutes.  Likewise, the (C)TATmCherry and 
TATmCherry reached maximum fluorescence in less than 7 minutes.  Based on this 
study, the TAT peptide does not show a difference in transduction efficiency or 












Figure 26.  Transduction of HEK293 cells with 5µm and 2.5µm eGFP-fusion 
proteins.  Cyclized (intein-based) and linear (wild-type) eGFP were used to measure 
the transduction capacity of the TAT-peptide.  5µm and 2.5µm of each protein (n=3) 
was incubated with adherent 293 cells for 2 hours.  Extracellular fluorescence was 
quenched with 10% total volume of 0.4% trypan blue and fluorescence was measured 
using 485nm excitation/516nm emission filter, and the average of reads was 
calculated.  The results shown are are the average of three replicates with one 




























Figure 27.  Short duration transduction analysis of (C)TATeGFP and (C)eGFP 
in 293 cells.  5µm of each fusion protein was incubated alongside HEK293 cells.  
Over 2-minute incriments, 10% total volume of 0.4% Trypan blue was added to 












(C)TATeGFP 0.39 0.69 ± 0.17 0.78 ± 0.14 
(C)eGFP 0.25 0.28 ± 0.16 0.36 ± 0.19 
Table 12.  First-order kinetic analysis of short duration transduction capacity of 
(C)TATeGFP and (C)eGFP fusion proteins in 293 cells.  The results shown are are 
the average of four replicates with one standard deviation.  
 
 
























Figure 28.  Transduction of HEK293 cells with 5µm and 2.5µm mCherry-fusion 
proteins.  Cyclized (intein-based) and linear (wild-type) mCherry were used to 
measure the transduction capacity of the TAT-peptide.  5µm and 2.5µm of each 
protein was incubated with adherent 293 cells for 2 hours.  Extracellular fluorescence 
was quenched with 10% total volume of 0.4% trypan blue and fluorescence was 
measured using 588nm excitation/509nm fluorescence.  The results shown are are the 










































Figure 29. Relative Fluorescence of TAT-fusion proteins incubated in PBS.  This 
figure measures the capacity of Trypan blue to quench extracellular fluorescence.  In 
this figure, the fluorescence was quenched with 10% (v/v) of 0.4% Trypan blue of 










































Figure 30. Transduction capacity of TAT-fluorescent protein fusions.  5µm and 
2.5µm of the fluorescent protein fusions were incubated for 120 minutes with 
HEK293 cells.  Extracellular fluorescence was quenched by addition of 10% volume 
0.4% trypan blue.  Intracellular fluorescence for eGFP (485ex/516em) and mCherry 
(580ex/610em) was measured for transduction of the TAT-fusion proteins.  The 






























































 Errork t0.5 (min) 
(C)TATeGFP 5.0 0.136 2.54E-02 5.09 
(C)TATeGFP 2.5 0.182 7.69E-03 3.80 
TATeGFP 5.0 0.132 1.44E-02 5.25 
TATeGFP 2.5 0.113 1.46E-02 6.13 
(C)eGFP 5.0 0.072 1.56E-02 9.62 
(C)eGFP 2.5 0.143 7.64E-02 4.84 
eGFP 5.0 0.179 5.19E-02 3.87 
eGFP 2.5 0.868 5.66E-01 0.79 
(C)TATmCherry 5.0 0.131 2.23E-02 6.13 
(C)TATmCherry 2.5 0.113 6.04E-02 5.29 
TATmCherry 5.0 0.127 1.73E+00 0.54 
TATmCherry 2.5 0.149 8.74E-02 4.64 
(C)mCherry 5.0 0.256 1.94E-01 2.70 
(C)mCherry 2.5 0.101 9.83E-03 6.83 
mCherry 5.0 0.171 1.02E-01 4.03 
mCherry 2.5 0.847 4.43E-01 0.82 
Table 13.  First-order rate constant and calculated fluorescent half-life of eGFP 
and mCherry fluorometric assay.  5µm and 2.5µm of eGFP and mCherry fusion 
proteins were incubated alongside HEK293 cells.  The extracellular fluorescence was 
modeled using exponential regression kinetics.  The half-life is the amount of time 



























Fmax     
Regression 
±s  
(C)TATeGFP 5.0 0.91 ± 5.14x10-2 0.85 7.98E-02 
(C)TATeGFP 2.5 0.81 ± 6.40x10-2 0.80 1.69E-02 
TATeGFP 5.0 1.00 ± 5.94x10-2 0.95 5.23E-02 
TATeGFP 2.5 0.92 ± 5.94x10-2 0.88 5.75E-02 
(C)eGFP 5.0 0.46 ± 1.67x10-2 0.42 4.58E-02 
(C)eGFP 2.5 0.29 ± 6.32x10-2 0.24 6.47E-02 
eGFP 5.0 0.41 ± 7.84x10-2 0.37 5.41E-02 
eGFP 2.5 0.35 ± 8.38x10-2 0.33 1.09E-01 
(C)TATmCherry 5.0 0.90 ± 8.66x10-2 0.85 8.42E-02 
(C)TATmCherry 2.5 0.76 ± 8.33x10-2 0.69 1.59E-01 
TATmCherry 5.0 1.00 ± 1.78x10-2 0.90 6.15E-01 
TATmCherry 2.5 0.81 ± 3.78x10-2 0.62 1.83E-01 
(C)mCherry 5.0 0.28 ± 7.46x10-2 0.35 1.35E-01 
(C)mCherry 2.5 0.28 ± 7.29x10-2 0.37 1.83E-02 
mCherry 5.0 0.28 ± 2.05x10-2 0.39 1.17E-01 
mCherry 2.5 0.28 ± 4.03x10-2 0.29 7.76E-02 
Table 14.  Maximum relative fluorescence of eGFP and mCherry Fluorometric 
Assay using experimental and regression analysis.  5µm and 2.5µm of eGFP and 
mCherry fusion proteins were incubated alongside HEK293 cells.  The extracellular 

























4.5.2 Long-term in vitro Assessment of (C)TATeGFP  
 
 Incubation of the (C)TATeGFP protein with HEK293 cells over a 3-day 
period demonstrated the in vitro stability of the cyclized protein.  After 24 and 48 
hours, the lysate fraction of the cells identified presence of eGFP in the (C)TATeGFP 
samples and not in the (C)eGFP samples.  The (C)TATeGFP samples at 72 hours 
could not identify the protein.  There was a time-dependent decrease of eGFP in the 
lysate fraction of the (C)TATeGFP samples.  The housekeeping protein, actin 
provided a loading control for all samples.   
 The in vitro transduction capacity of TATeGFP proteins in a cell culture 
environment has been previously studied.  The detection of eGFP in the lysate 
fraction has been identified on an anti-GFP western blot after 48 hours [212] and 72 
hours [213].  The results in this experiment are comparable to the linear eGFP models 
discussed in literature.  Therefore, the cyclized eGFP protein retains the in vitro 
transduction capacity.   
Although a western blot does not provide evidence of native-folding protein 
structure, the (C)TATeGFP protein retained transduction capacity for 48 hours.  As 
discussed earlier, bioavailability is a critical parameter of therapeutic proteins.  Upon 
administration, the human body’s natural defense system efficiently degrades 
exogenous proteins. In vivo efficacy is heavily predicated on the half-life of a 
therapeutic protein.  In this study, we have determined that a cyclic protein retains 







Figure 31. Anti-gfp and Anti-actin western blot of time-course samples of 
HEK293 lysates treated with (C)TATeGFP and (C)eGFP.  5µM of the purified 
protein was added to 5x105 viable cells in a 6-well plate.  After 24, 48, and 72 hours 
the cells were detached with trypsin and washed 3x with PBS.  The lysate fraction 








 In this study, a cyclized, cell-penetrating peptide-protein system transduced 
the cell membrane and delivered a functional fluorometric reporter.  The penetration 
of the macromolecule through the cell membrane exhibited low cytotoxicity.  The 
kinetic rate and transduction efficiency of the cyclized fluorometric reporter was 
comparable to the linear-counterpart—a protein expressed without the intein-based 
system.  The cell-penetrating peptide demonstrated robustness through delivery of 
two different fluorometric reporters, eGFP and mCherry, with comparable rate and 
efficiency.  Finally, the enhanced stability of the cyclized fluorometric reporter, as 
discussed previously in Chapter 3, was orthogonally measured as the cyclical protein 
retained transduction capacity for at least 48 hours when co-cultured with mammalian 
cells.   
 There are two experimental discoveries in this chapter: the effective cellular 
uptake of a cyclized, fluorometric reporter, and the in vitro stability of the cyclized 
protein in 293 cells.  As previously discussed in Chapter 3, the cyclized protein 
enhances the stability against protein degradation.  This chapter demonstrates that 
inclusion of the TAT-peptide in the eGFP, intein fusion protein facilitates the cellular 
uptake, comparable to the linear counterpart.  Transduction efficiency and, defined by 
the relative maximum fluorescence, and rate of transduction, measured by the 
fluorescence half-life were comparable to previous published results of the linear 
TATeGFP protein.  An additional supporting piece of evidence that cyclized proteins 
retain cellular uptake capacity is the demonstration of in vitro transduction after 48 




structure necessary for fluorescence, however, the fusion protein retained the capacity 



























 A unique cell-penetrating fluorometric reporter system has been engineered 
for enhanced stability while maintaining transduction potential.  This study combined 
post-translational intein-splicing to form a cyclical protein with the cell transduction 
potential of the TAT-peptide.  Fluorescent fusions retained native-state folding after 
transduction of the cell membrane.  Orthogonal methods have been presented to 
confirm the cyclic, post-translational structure of the fluorometric reporters.  The 
cyclical fluorometric reporters were resistant to exopeptidases and retained 
fluorescence at high concentrations of a chaotropic agent.  The results of the 
experiment detail a fluorometric reporter system that has enhanced stability during 
protein expression, resistance to destabilization of hydrophobic interactions from 
chaotropic agents, resistance to exopeptidase digestion, and a rapid transduction 
across the cell membrane of eukaryotic cells.   
 A protein manufacturing process should produce a properly folded protein 
with high yields under a robust and reproducible platform.  The protein expression 
phase sets the benchmark for overall yield of the process. It is critical to establish a 
production process that offers robustness in the relative stability of the protein.  
Protease degradation and thermal instability of exogenous proteins reduce yields and 
force execution of a harvest prior to the maximum yield of the process.  A protein 
expressed as a cyclical structure creates an opportunity to increase yields during the 




reduce the manufacturing cost providing cost savings to the patient—the most critical 
stakeholder in the drug development process.    
 A cyclic, cell-penetrating, fluorometric reporter system could provide real-
time tracking and identification of malignant tumors.  It is unknown the full potential 
of the Maternin peptide.  Through published results, it appears to be a peptide with 
immense potential.  It is possible the peptide has selective function with cells 
expressing CD133+/CD44+ surface markers, uniquely identifying cancer cells.  A 
fusion protein of Maternin, a cell-penetrating peptide and a fluorometric reporter 
could selectively identify, transduce and fluoresce cancer cells.  As a diagnostic tool, 
the fusion protein could be orally ingested as the cyclical backbone could offer 
enhanced stability from the low pH environment and high concentration of proteases 
found in the digestive track.  Upon entry into the bloodstream, the fluorometric 
reporter could be tracked with a non-invasive sensor as it circulates through the body.  
Upon positive identification, the fluorometric reporter penetrates the cell membrane 
and identifies the cancer cells.  The system could also be engineered to remain in an 
endocytosis-induced vesicle which could enhance the residence time of the molecule 
ensuring proper identification and location.   
 
5.2 Future Work 
 
 The future direction of this work is to study the integration of the Maternin 
peptide into a cyclical, cell-penetrating fluorometric reporter.  The low efficacy of the 
cyclized Maternin-eGFP fusion protein led to the study of cell-penetrating peptides.  




several locations on the eGFP backbone.  The published crystal structures of eGFP 
illustrate exposed N-terminal and C-terminal amino acids.  Therefore, additional sites 
could be employed of regions in the eGFP beta-barrel that are exposed—specifically 
on surface loop of eGFP: gfp157 or gfp172 [214].  A cyclic Maternin-eGFP could be 











A pET21(a)+ vector with 564bp insert encoding nucleotide sequences for three target 
protein fragments: InteinC, 14 amino acid peptide (Maternin), and InteinN.  Post-
translational features of the translated sequence include an C-terminal His-tag (6 
repeated residues) followed by a stop codon (TAA).  Enzymatic digest sites included 
are: 
NdeI  N-terminal  
HindIII Enclosed by InteinC and Maternin 
EcoRI  Enclosed by Maternin and InteinN 
XhoI  C-terminal nucleotide sequence following stop codon (TAA) 
 
Plasmid Construction: 
The 564bp nucleotide sequence was synthesized by ThermoFisher (Carlsbad, CA) 
and inserted into a proprietary vector.  The vector was digested with NdeI and XhoI, 
and agarose-gel purified.  The digested fragment was ligated into a digested 
pET21(a)+ vector [NdeI/XhoI] and transformed into DH5-alpha competent cells 
(ThermoFisher).  The competent cells were cultured in LB media containing 
50µg/mL Ampicillin and plasmid was extracted from cell lysates.  Purified plasmid 
was transformed into Rosetta(DE3) Competent Cells (Novagen).   
  
  
Figure 32.  1.5% (w/v) Agarose gel separating a digested 
pET21(a)+ vector containing Cint.14mer.Nint.6H with NdeI / 
XhoI.  Lane 1 is a 1kb DNA Ladder (Thermo) and Lane 2 is the 
digested plasmid.  A band is observed between 500-750bp that 





A.2  pET21a-Cint.14His.NInt.6H 
 
A pET21(a)+ vector with 564bp insert encoding nucleotide sequences for three target 
protein fragments: InteinC, 14 histidine residues, and InteinN.  Post-translational 
features of the translated sequence include an C-terminal His-tag (6 repeated 
residues) followed by a stop codon (TAA).  Enzymatic digest sites included are: 
NdeI  N-terminal  
HindIII Enclosed by InteinC and 14 histidine 
EcoRI  Enclosed by 14 histidines and InteinN 
XhoI  C-terminal nucleotide sequence following stop codon (TAA) 
 
Plasmid Construction: 
The 564bp nucleotide sequence was synthesized by ThermoFisher (Carlsbad, CA) 
and inserted into a proprietary vector.  The vector was digested with NdeI and XhoI, 
and agarose-gel purified.  The digested fragment was ligated into a digested 
pET21(a)+ vector [NdeI/XhoI] and transformed into DH5-alpha competent cells 
(ThermoFisher).  The competent cells were cultured in LB media containing 
50µg/mL Ampicillin and plasmid was extracted from cell lysates.  Purified plasmid 
was transformed into Rosetta(DE3) Competent Cells (Novagen).   
 
  
Figure 33. 1.5% (w/v) Agarose gel separating a 
digested pET21(a)+ vector containing 
Cint.14HIS.Nint.6H with NdeI / XhoI.  Lane 1 is a 
1kb DNA Ladder (Thermo) and Lane 2 is the digested 
plasmid.  A band is observed between 500-750bp that 








A pET21(a)+ vector with 1236bp insert encoding nucleotide sequences for three 
target protein fragments: InteinC, egfp, and InteinN.  Post-translational features of the 
translated sequence include an C-terminal His-tag (6 repeated residues) followed by a 
stop codon (TAA).  Enzymatic digest sites included are: 
NdeI  N-terminal  
HindIII Enclosed by InteinC and egfp 
EcoRI  Enclosed by egfp and InteinN 
XhoI  C-terminal nucleotide sequence following stop codon (TAA) 
 
Plasmid Construction: 
The 1236bp nucleotide sequence was synthesized by ThermoFisher (Carlsbad, CA) 
and inserted into a proprietary vector.  The vector was digested with NdeI and XhoI, 
and agarose-gel purified.  The digested fragment was ligated into a digested 
pET21(a)+ vector [NdeI/XhoI] and transformed into DH5-alpha competent cells 
(ThermoFisher).  The competent cells were cultured in LB media containing 
50µg/mL Ampicillin and plasmid was extracted from cell lysates.  Purified plasmid 
was transformed into Rosetta(DE3) Competent Cells (Novagen).   
  
Figure 34. 1.5% (w/v) Agarose gel separating a 
digested pET21(a)+ vector containing 
Cint.gfp.Nint.6H with NdeI / XhoI.  Lane 1 is a 1kb 
DNA Ladder (Thermo) and Lane 2 is a digested 
pET21(a)+ vector without the target insert.  Lane 3 is 
the digested plasmid containing the target insert.  A 
band is observed between 1000-1500bp that indicates 







A pET21(a)+ vector with 1320bp insert encoding nucleotide sequences for three 
target protein fragments: InteinC, egfp, and InteinN.  Post-translational features of the 
translated sequence include an N-terminal His-tag (6 repeated residues) at the C-
terminus of the egfp nucleotide sequence.  Then the 14mer peptide is flanked by 
TEV-protease recognition sites (ENLYFQS). A stop codon (TAA) follows the InteinN 
nucleotide sequence.  Enzymatic digest sites included are: 
NdeI  N-terminal  
HindIII Enclosed by InteinC and egfp 
EcoRI  Enclosed by egfp and InteinN 
XhoI  C-terminal nucleotide sequence following stop codon (TAA) 
 
Plasmid Construction: 
A 938bp nucleotide sequence was synthesized by ThermoFisher (Carlsbad, CA) to 
encode the nucleotide sequence for translation of egfp.6H.TEV.14mer.TEV.  At the 
N-terminus, five nucleotides (CGCCG) preceded the HindIII recognition site and 
following the EcoRI recognition site to allow for effective enzymatic digestion. The 
vector was digested with HindIII and EcoRI, and agarose-gel purified.  The digested 
fragment was ligated into a digested pET21a-Cint.14His.NInt.6H vector [HindIII / 
EcoRI] and transformed into DH5-alpha competent cells (ThermoFisher).  The 
competent cells were cultured in LB media containing 50µg/mL Ampicillin and 
plasmid was extracted from cell lysates.  Purified plasmid was transformed into 
Rosetta(DE3) Competent Cells (Novagen).   
  
Figure 35. 1.5% (w/v) Agarose gel separating a digested 
pET21(a)+ vector containing Cint. gfp.6H.TEV.14mer.TEV.Nint 
with HindIII / EcoRI.  Lane 1 is a 1kb DNA Ladder (Thermo) and 
Lane 2 is the digested plasmid.  A band is observed between 750-






A pET21(a)+ vector with 2817bp insert encoding nucleotide sequences for four target 
protein fragments: InteinC, egfp, and InteinN, and AIDA-1.  Post-translational features 
of the translated sequence include pET21a-Cint.egfp.6H.TEV.14mer.TEV.NInt 
with a C-terminal AIDA-1 autotransporter linker sequence. A stop codon (TAA) 
follows the AIDA-1 nucleotide sequence.  Enzymatic digest sites included are: 
NdeI  N-terminal  
HindIII Enclosed by InteinC and egfp 
EcoRI  Enclosed by egfp and InteinN 
BamHI Enclosed by InteinN and AIDA-1 
XhoI  C-terminal nucleotide sequence following stop codon (TAA) 
 
Plasmid Construction: 
The 1497bp nucleotide sequence encoding AIDA-1 was PCR amplified from a 
pET200 plasmid from J. Terrell (Forward CCGGGATTCGGTACCGTTAACA 
ATAATGG) and (Reverse CCGGAAGCTATATTTGATACCCAGTGCACCG 
CTAATGG.)  The primers added a BamHI recognition site at the N-terminus and a 
stop codon (TAA) followed by XhoI at the C-terminus. The 1320bp 
Cint.egfp.6H.TEV.14mer.TEV.NInt insert was PCR amplified from pET21a-
Cint.egfp.6H.TEV.14mer.TEV.NInt (Forward 
GCGCATATGGTGAAAGTTATTGG) and Reverse 
GCGTTTGATGGTGCCTGCATCCAGCAGCGG).  The N-terminal NdeI was 
retained and the C-terminal amino acid sequence of InteinN was followed by a 
BamHI recognition site.  The AIDA-1 PCR amplicon was digested with BamHI and 
XhoI, the Cint.egfp.6H.TEV.14mer.TEV.NInt amplicon was digested with NdeI 
and BamHI and ligated into a NdeI / XhoI digested pET21(a)+ vector and 
transformed into DH5-alpha competent cells (ThermoFisher).  The competent cells 
were cultured in LB media containing 50µg/mL Ampicillin and plasmid was 
extracted from cell lysates.  Purified plasmid was transformed into Rosetta(DE3) 















A.6. pET21a-SP.Cint.egfp.6H.TEV.14mer.TEV.NInt.AIDA1 and pET21a-
Cint.egfp.6H.TEV.14mer.TEV.NInt.AIDA1.   
 
A pET21(a)+ vector with 2973bp insert encoding nucleotide sequences for four target 
protein fragments: InteinC, egfp, and InteinN, and AIDA-1.  Post-translational features 
of the translated sequence include an N-terminal AIDA-1 signal peptide, and 
pET21a-Cint.egfp.6H.TEV.14mer.TEV.NInt.AIDA1.  Enzymatic digest sites 
included are: 
NdeI  N-terminal  
SalI  Enclosed by Signal Peptide and InteinC 
HindIII Enclosed by InteinC and egfp 
EcoRI  Enclosed by egfp and InteinN 
BamHI Enclosed by InteinN and AIDA-1 
XhoI  C-terminal nucleotide sequence following stop codon (TAA) 
 
Plasmid Construction: 
The 150bp nucleotide sequence encoding the AIDA-1 signal peptide was PCR 
amplified from a pET200 plasmid from J. Terrell (Forward 
CCGCATATGAACAAAGCCTACAGCATCATTTGG) and (Reverse 
Figure 36. 1.5% (w/v) Agarose gel separating a digested 
pET21(a)+ vector containing pET21a-
Cint.gfp.6H.TEV.14mer.TEV.NInt.AIDA1 with HindIII / XhoI.  
Lane 1 is a 1kb DNA Ladder (Thermo) and Lane 2 is the digested 
plasmid.  A band is observed between 2500-3000bp that indicates 




CCGGTCGACTGCAAATGCATTACCAATGG.)  The primers added a NdeI 
recognition site at the N-terminus and a SalI at the C-terminus. The 2817bp 
Cint.egfp.6H.TEV.14mer.TEV.NInt .AIDA1 insert was PCR amplified from 
pET21a- SP.Cint.egfp.6H.TEV.14mer.TEV.NInt.AIDA1 
 (Forward GCGAGTCGACATGGTTAAAGTTATTGG) and Reverse 
GCGTTTGATGGTGCCTGCATCCAGCAGCGG).  An N-terminal SalI was inserted 
and the C-terminal amino acid sequence was maintained.  The Signal Peptide PCR 
amplicon was digested with NdeI and SalI, the 
Cint.egfp.6H.TEV.14mer.TEV.NInt.AIDA1 amplicon was digested with SalI and 
XhoI and ligated into a NdeI / XhoI digested pET21(a)+ vector and transformed into 
DH5-alpha competent cells (ThermoFisher).  The competent cells were cultured in 
LB media containing 50µg/mL Ampicillin and plasmid was extracted from cell 
lysates.  Purified plasmid was transformed into Rosetta(DE3) Competent Cells 















Figure 37. 1.5% (w/v) Agarose gel separating a digested 
pET21(a)+ vector containing pET21a-
Cint.gfp.6H.TEV.14mer.TEV.NInt.AIDA1 with HindIII / XhoI.  
Lane 1 is a 1kb DNA Ladder (Thermo) and Lane 2 is the digested 
plasmid.  A band is observed between 2500-3000bp that indicates 




A.7. pET21a-Cint.egfp.Thr.6H.Nint, pET21a-Cint.egfpnoc.Thr.6H.Nint (C49G 
and C71G), and pET21a-Cint.egfpind.Thr.6H.Nint (C49G, V69P, Q70L, F72L) 
 
A pET21(a)+ vector with 1236bp insert encoding nucleotide sequences for three 
target protein fragments: InteinC, egfp, and InteinN.  Post-translational features of the 
translated sequence include an C-terminal Thrombin recognition site, a His-tag (6 
repeated residues).  A stop codon (TAA) follows the InteinN nucleotide sequence.  
Enzymatic digest sites included are: 
NdeI  N-terminal  
HindIII Enclosed by InteinC and egfp 
EcoRI  Enclosed by egfp and InteinN 
XhoI  C-terminal nucleotide sequence following stop codon (TAA) 
 
Plasmid Construction: 
414bp nucleotide sequences was synthesized by ThermoFisher (Carlsbad, CA) and 
inserted into a proprietary vector.  The sequences were flanked by enzymatic 
recognition sites HindIII and ClaI at the N-terminus and C-terminus respectively.  
The vector was digested with HindIII and ClaI, and agarose-gel purified.  The 
digested fragment was ligated into a digested pET21a-
Cint.egfp.6H.TEV.14mer.TEV.NInt 
vector [HindIII/ClaI] and transformed into DH5-alpha competent cells 
(ThermoFisher). Sequences were confirmed by nucleotide sequencing using 




Figure 38. 1.5% (w/v) Agarose gel separating a digested 
pET21(a)+ vector containing pET21a-Cint.gfp.Thr.6H.NInt; 
pET21a-Cint.gfpnoc.Thr.6H.NInt; pET21a-
Cint.gfpind.Thr.6H.NInt  
 with NdeI / XhoI.  Lane 1 is a 1kb DNA Ladder (Thermo) and 
Lane 2 is a digested pET21a-Cint.gfp.Thr.6H.NInt; Lane 3 is 
digested pET21a-Cint.gfpnoc.Thr.6H.NInt; Lane 4 is digested 
pET21a-Cint.gfpind.Thr.6H.NInt.  All vectors were digested with 
NdeI and XhoI.  Bands are observed between 1000-1500bp that 






















(C)eGFP-1ug/ml	 164	 4.62	 82.0%	 2.31E-02	 63.52%	 7.13E-02	
(C)eGFP-5ug/ml	 165	 4.16	 82.5%	 2.08E-02	 63.90%	 7.06E-02	
(C)eGFP-10ug/ml	 162	 2.16	 81.0%	 1.08E-02	 62.74%	 6.84E-02	
(C)Maternin-eGFP-
1ug/ml	
164.5	 3.11	 82.3%	 1.55E-02	 63.71%	 6.93E-02	
(C)Maternin-eGFP-
5ug/ml	
162	 1.41	 81.0%	 7.07E-03	 62.74%	 6.79E-02	
(C)Maternin-eGFP-	
10ug/ml	
167.75	 2.22	 83.9%	 1.11E-02	 64.97%	 6.84E-02	
Synthetic	Maternin-
1ug/ml	
41.75	 2.06	 20.9%	 1.03E-02	 16.17%	 6.83E-02	
Synthetic	Maternin-
5ug/ml	
32	 2.16	 16.0%	 1.08E-02	 12.39%	 6.84E-02	
Synthetic	Maternin-
10ug/ml	
21.75	 1.71	 10.9%	 8.54E-03	 8.42%	 6.80E-02	
Taxol-1ug/ml	 28.5	 1.29	 14.3%	 6.45E-03	 11.04%	 6.78E-02	
Taxol	-	5ug/ml	 13.5	 1.29	 6.75%	 6.45E-03	 5.23%	 6.78E-02	
Taxol-10ug/ml	 8.75	 1.71	 4.38%	 8.54E-03	 3.39%	 6.80E-02	
Control	 181	 2.16	 90.5%	 1.08E-02	 70.10%	 6.84E-02	
















(C)eGFP-1ug/ml	 136	 2.63	 67.9%	 1.31E-02	 92.66%	 2.61E-02	
(C)eGFP-5ug/ml	 137	 4.03	 68.4%	 2.02E-02	 93.34%	 3.02E-02	
(C)eGFP-10ug/ml	 136	 2.16	 68.0%	 1.08E-02	 92.83%	 2.50E-02	
(C)Maternin-eGFP-
1ug/ml	
137	 2.06	 68.4%	 1.03E-02	 93.34%	 2.48E-02	
(C)Maternin-eGFP-
5ug/ml	
133	 3.20	 66.6%	 1.60E-02	 90.96%	 2.77E-02	
(C)Maternin-eGFP-	
10ug/ml	
135	 4.76	 67.5%	 2.38E-02	 92.15%	 3.28E-02	
Synthetic	Maternin-
10ug/ml	
20.8	 0.957	 10.4%	 4.79E-03	 14.16%	 2.30E-02	
Synthetic	Maternin-
5ug/ml	
16.3	 1.50	 8.13%	 7.50E-03	 11.09%	 2.38E-02	
Synthetic	Maternin-
1ug/ml	









Mean	 St.	Dev	 PE	 St.	Dev	 SF	 St	Dev.	
Taxol-1ug/ml	 17.5	 2.08	 8.75%	 1.04E-02	 11.95%	 2.48E-02	
Taxol	-	5ug/ml	 14.8	 1.71	 7.38%	 8.54E-03	 10.07%	 2.41E-02	
Taxol-10ug/ml	 8.50	 1.29	 4.25%	 6.45E-03	 5.80%	 2.35E-02	
Control	 147	 4.51	 73.3%	 2.25E-02	 100%	 3.19E-02	
















(C)eGFP-1ug/ml	 114	 3.40	 57.1%	 1.70E-02	 86.88%	 2.23E-02	
(C)eGFP-5ug/ml	 113	 2.63	 56.6%	 1.31E-02	 86.12%	 1.95E-02	
(C)eGFP-10ug/ml	 115	 4.80	 57.3%	 2.40E-02	 87.07%	 2.80E-02	
(C)Maternin-eGFP-
1ug/ml	
115	 3.50	 57.6%	 1.75E-02	 87.64%	 2.27E-02	
(C)Maternin-eGFP-
5ug/ml	
116	 2.63	 57.9%	 1.31E-02	 88.02%	 1.95E-02	
(C)Maternin-eGFP-	
10ug/ml	
115	 2.94	 57.5%	 1.47E-02	 87.45%	 2.06E-02	
Synthetic	Maternin-
1ug/ml	
38.0	 1.83	 19.0%	 9.13E-03	 28.90%	 1.71E-02	
Synthetic	Maternin-
5ug/ml	
20.5	 1.29	 10.3%	 6.45E-03	 15.59%	 1.58E-02	
Synthetic	Maternin-
10ug/ml	
13.0	 1.83	 6.50%	 9.13E-03	 9.89%	 1.71E-02	
Taxol-1ug/ml	 32.5	 2.38	 16.3%	 1.19E-02	 24.71%	 1.87E-02	
Taxol	-	5ug/ml	 22.0	 2.94	 11.0%	 1.47E-02	 16.73%	 2.06E-02	
Taxol-10ug/ml	 12.3	 1.71	 6.13%	 8.54E-03	 9.32%	 1.68E-02	
Control	 132	 2.89	 65.8%	 1.44E-02	 100%	 2.04E-02	
Table 15.  Plating Effeciency and Survival Fraction of Compounds tested on 
HTB-123, PC-3, and KSY-1 Cells.  Control (PBS), Taxol, Synthetic Maternin, 
(C)Maternin-eGFP, and (C)eGFP were incubated at 10µg/mL, 5µg/mL, 1µg/mL for 7 













Appendix C.  Fluorescence and Optical Density Measurements during Protein 
Expression of eGFP, TATeGFP, and (C)TATeGFP 
 


















Avg St. Dev 1 2 3 4 5 
eGFP N/A 740 680 810 720 800 750 54.8 
0.3mM 890 1100 980 920 860 950 94.9 
0.1mM 840 830 910 870 930 876 43.4 
0.03mM 870 920 850 840 960 888 50.7 
0.01mM 650 650 680 740 710 686 39.1 
TATeGFP N/A 840 790 860 770 790 810 38.1 
0.3mM 940 960 870 970 870 922 48.7 
0.1mM 800 1010 1000 830 880 902 93.9 
0.03mM 660 680 710 780 800 726 61.5 
0.01mM 730 760 770 770 750 756 16.7 
(C)TATeG
FP 
N/A 620 600 660 660 840 676 95.3 
0.3mM 920 870 860 990 1030 934 74.4 
0.1mM 930 770 940 880 870 878 67.6 
0.03mM 850 780 890 750 680 790 82.8 
0.01mM 520 640 650 730 590 626 77.7 
Table 16. Maximum fluorescence of eGFP, TATeGFP, and (C)TATeGFP 
constructs during induction over half-log increments of 0.01mM, 0.03mM, 
0.1mM, and 0.3mM IPTG.  Fluorescence was measured every 10 minutes and the 
maximum signal was determined for the three eGFP variants over four IPTG 











































































Figure 39.  Relative Fluorescence after maximum during induction of eGFP, 
TATeGFP, and (C)TATeGFP using half-log concentrations of 0.01mM, 0.03mM, 
0.1mM, and 0.3mM IPTG.  (C)TATeGFP (Frame A), TATeGFP (Frame B), and 
eGFP (Frame C) all experience higher expression as the IPTG concentration is 
increased from 0.01mM, 0.03mM, 0.1mM, and 0.3mM IPTG.  After the maximum 
flourescence is observed during induction, equilibrium exists between protein 
expression and proper folding of eGFP and the degredation that is induced from 
intracellular and extraceullar factors.   
C.2 Exponential Regression Analysis  
 
For regression analysis of exponential functions, Microsoft Excel’s Solver function 
was used to minimize the sum of squares.  The standard error of the exponential 
function coefficients were calculated from Bayesian probability theory [215]: 
 




8ä…Δ7 , t~time scale of measurement   Equation 28 
Standard Error of Maximum Fluorescence: 
 








































Appendix D.  Effect of divalent ions as a catalyst for post-translational intein 
processing 
 
Homing endonucleases require a co-factor for efficient cleavage and site-specificity 
of supercoiled DNA [216].  Intein endonucleases require a divalent ion as a cofactor.  
The intein endonuclease from the DNA polymerase enzyme of Thermococcus 
fumicolans is 5-10 fold more active in the presence of Mn2+ over Mg2+ [217].  Intein-
induced cleavage of proteins is most efficient under reducing conditions [218] and 
strongly inhibited by divalent ions [219]. 
D.1.  Materials and Methods 
 
Plasmid pET21a-Cint.egfp.6H.TEV.14mer.TEV.Nint [A.4. pET21a-
Cint.egfp.6H.TEV.14mer.TEV.Nint] was used to express (C)eGFP as described in 
[2.3.1 Protein Expression].  The frozen cell pellet was fractioned into two aliquots.  
One aliquot was resuspended in IMAC Load/Lyse buffer, pH 6.5 and the second in 
IMAC Load/Lyse buffer, pH 8.5 [G.2  IMAC Column Buffers] The resuspended 
cell pellets were lysed as described in [2.3.2 IMAC Purification] and the clarified 
lysate fraction was separated into ten, 5mL fractions.  Fractions (n=3) were 
supplemented with the following a reducing agent and/or divalent cation as described 
















1 1mM TCEP 25mM Ca2+ 
2 50mM DTT 25mM Ca2+ 
3 --- 25mM Ca2+ 
4 1mM TCEP 25mM Mg2+ 
5 50mM DTT 25mM Mg2+ 
6 --- 25mM Mg2+ 
7 1mM TCEP 1mM Zn2+ 
8 50mM DTT 1mM Zn2+ 
9 --- 1mM Zn2+ 
10 --- --- 
Table 17.  Divalent ion and reducing agent supplimentation of (C)eGFP lysate 
fractions for on-column intein processing.  The 10 fractions (n=3) were purified 
using an IMAC column to assess the intein processing effeciency. 
 
The 5mL supplemented fractions were loaded onto charged IMAC columns and 
washed once with IMAC wash buffer.  The columns were stored at 4°C for 16 hours.  
The columns were eluted with IMAC elution buffer.  The elution fraction was 
analyzed using a Biotek Neo2 for absorbance at 280nm (total protein) and 475nm 
(eGFP fluorescence emission maximum).  The elution fractions were loaded onto a 4-
15% reducing SDS-PAGE gel (Biorad) and separated at 200V for 45 minutes.  The 
gel was stained in 0.1% coomassie blue and de-stained with ethanol/acetic acid.  
Band densitometry analysis was performed on four key intein process fragments: 
unprocessed intein (50kDa), eGFP-Cintein (34kDa), eGFP (30kDa), and Nintein 
(14kDa). 
 To quantify the efficiency of intein processing using orthogonal methods, the 
optical density and band densitometry were used to compare reducing agents, divalent 
ions, and pH conditions.  For optical density, the intein processing efficiency was 











    Equation 30 
For band densitometry, a ratio was calculated to quantify the intein processing 
efficiency: 
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    Equation 31 
 
D.2.  Results and Analysis 
 
 IMAC purified samples of (C)eGFP expressed protein lysates, supplemented 
with reducing agents and divalent ions, over acidic and basic conditions, exhibited 
differences in the efficiency that a translated intein sequence is processed.  As 
discussed in the literature review and the introduction section to Appendix C, intein 
processing has referenced protocols including divalent ions and or reducing agents to 
enhance the efficiency that a translated intein sequence processes the final intein 
fragments.  For this experiment, the goal was to enhance the processing of the intein, 
resulting in a cyclized-eGFP protein.  Moreover, results of this experiment would 
outline the most efficient method for protein production and purification for 
subsequent intein-related analysis. 
 After purification of the lysate fractions, the first method used to evaluate 
intein processing was the relative fluorescence of the elution samples.  As illustrated 
in 2.3.4 Size Exclusion Purification of eGFP-variants, the relative fluorescence of 
unprocessed intein fragments is minimal.  Therefore, if total protein can be quantified 
by absorbance at 280nm and eGFP fluorescence has a maximum absorbance at 
475nm, a ratio of these two wave lengths will correlate to relative concentration of 




processing under acidic (pH 6.5) or basic (pH 8.5) conditions.  However, there is a 
significant difference upon supplementation of divalent ions and reducing agents.  
Based on the data in the figure, the optimal condition is supplementing with 1mM 
DTT, and 25mM CaCl2. pH 6.5.  Intein processing efficiency is reduced when 
supplementing with Zn2+, and is reversible by supplementing with a reducing agent. 
 
Figure 40. Divalent and reducing agent analysis of on-column intein processing.  
(C)eGFP cell pellets (n=3) were lysed using one of two reducing agents (1mM TCEP 
or 50mM DTT), one of three divalent ions (25mM CaCl2, 25mM MgCl2, or 1mM 
ZnCl2), or 2 pH conditions (pH 6.5 or pH 8.5), and a negative control and purified 
using an IMAC column.  After the binding step, the column was washed and then 
incubated at 4°C for 16 hours before washing and eluting the sample.  The elution 
samples were measured for absorbance at 280nm (total protein) and 475nm (eGFP).  
For the graph, the absorbance at 475 was normalized by 280nm.  The results shown 
are are the average of three replicates with one standard deviation.  
 
 
From Figure 3, the processing of the Lactam Intein results in two products: a Nintein 
fragment and a eGFP-Cintein fragment.  Therefore, if the process were inhibited at this 
step, these two fragments should be formed in relatively equal molar quantities.  

















When the lactam product is further processed, it results in two products, a Cintein 
fragment and a cyclized eGFP protein.  Therefore, upon full intein processing, the 
molar ratio of Nintein to eGFP-Cintein should be >1.  This is difficult to correlate in 
Figure 42 as the Nintein fragment does not contain a His-tag.  Any lactam processing 
prior to this experiment would produce an Nintein fragment that would collect in the 
column flowthrough or wash sample.  Analysis of molar ratios of the Nintein to eGFP-
Cintein would not be accurate unless the flowthrough and wash fractions were included 
in the molar balance. 
While it is difficult to observe intein processing efficiency from the SDS-PAGE gel 
illustrated in Figure 41, the band densitometry analysis does provide basis for 
supporting hypothesis that Zn2+ is inhibitory to intein processing.  A relative intein 
efficiency can be calculated to compare the samples tested in this experiment.  A 
dense unprocessed intein protein band with respect to a lower absorbance at 280nm 
would indicate a high percentage of unprocessed inteins.  Therefore, if Zn2+ were 
inhibitory, it would have the highest ratio.  If we consider it an efficiency ratio, then it 
can be calculated as illustrated in  





    Equation 32 
 
 






















Figure 41.  Band densitometry analysis using reducing SDS-PAGE gel of intein 
fragments.  Elution samples were separated using a reducing-protein gel and the four 
intein fragments: unprocessed intein (50kDa), eGFP-Cintein (34kDa), eGFP (30kDa), 


















2 DTT, CaCl2 
3 TCEP, CaCl2 
4 CaCl2 
5 DTT, ZnCl2 
6 TCEP, ZnCl2 
7 ZnCl2 
8 DTT, MgCl2 
9 TCEP, MgCl2 
10 MgCl2 







Figure 42. Intein process of on-column samples using reducing agents, divalent 
ions, and pH.  Elution samples of overnight-bound intein samples supplimented with 
one of two reducing agents (1mM TCEP or 50mM DTT), one of three divalent ions 
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(25mM CaCl2, 25mM MgCl2, or 1mM ZnCl2), or 2 pH conditions (pH 6.5 or pH 8.5), 
and a negative control and purified using an IMAC column.  The elution sample was 
separated using a reducing SDS-PAGE gel and stained with coomassie blue.  The 
stained gel (Figure 41) was analyzed for protein band area using a Biorad Chemidoc 
Imaging System.  The four bands analysed: Unprocessed Intein (50kDa), eGFP-
Cintein (34kDa), eGFP (30kDa), and Nintein (14kDa). 
 
Figure 43.  Relative intein effeciency of (C)eGFP samples supplimented with 
divalent ions or reducing agents at pH 6.5 and pH 8.5.  Using the densitometry 
analysis from Figure 41, and the total protein absorbance at 280nm from Figure 40, a 
relative intein effeciency can be calculated.  Adding Zn2+ to samples inhibits intein 





The motivation for this experiment was to investigate optimal conditions for intein 
processing.  Performing an experiment to measure intein processing is difficult based 
on the number of steps required for precise analytical measurements.  This 
experiment used semi-pure samples to perform fluorescence and densitometry 
analysis.  Performing a molar balance on the intein fragments would be a streamlined 
approach for intein processing efficiency, however, some of the fragments would not 

















bind and elute under the same conditions.  Therefore, orthogonal measurements were 
employed to select a divalent ion, reducing agent, and pH for further studies that 
required purified inteins.   
Based on literature review, Zn2+ was inhibitory, and Mg2+, Ca2+ and either 
DTT or TCEP would enhance intein processing.  The fluorescence to total protein 
ratio (Equation 30) confirmed that Zn2+ was inhibitory and could be reversible with 
DTT or TCEP.  Using densitometry analysis, coupled with total protein absorbance at 
280nm, Zn2+ inhibited intein processing was confirmed.  All lysis and purification 

















Appendix E.  Effect of coding ligation-enhancing intein fragments for internal 
cyclization of target proteins 
 
The SSp DnaE intein contains two translated fragments: the DnaE-N and DnaE-C 
proteins which catalyze the excision of a cyclized protein.  The natural amino acid 
coding sequence of the DnaE-N protein has a Cys at the N-terminal position and the 
DnaE-C has a Gly or Ala on the C-terminal position [72].  The protein cyclization 
efficiency can be enhanced by coding for a Ser Gly as the N-terminal and Pro Lys as 
the C-terminal amino acids of the target cyclic protein [79].  In this experiment, a 
hypothesis is tested that including an engineered amino acid sequence in the target 
cyclic protein can induce internal ligation.  The wild type eGFP sequence had all Cys 
deleted from the 238-amino acid sequence and replaced by Gly: C49G, and C71G.  
The N-terminal Cys on the DnaE-N is responsible for the internal thiol nucleophile 
attack.  Deletion of the Cys will prevent any internal residues from executing a 
nucleophile attack.  Then, the engineered ligation site is inserted: Pro Lys Cys Lys.  
This sequence contains the two C-terminal amino acids from the target cyclized 
protein and the two N-terminal amino acids from the DnaE-C protein: V69P Q70L 
G71C F72L.  If the hypothesis were true, a 15kDa protein could be observed which 
would indicate the internal ligation sequence activated the split-intein protein splicing 
mechanism.  Three proteins studied in this experiment were the wild type eGFP 
(eGFP), wild type eGFP, C49G, C71G, (C)eGFP-GG, and wild type eGFP C49G, 






D.1.  Materials and Methods 
 
The plasmids containing coding sequences for the three target proteins: (C)eGFP, 
(C)eGFP-GG, and (C)eGFP-PLCL were constructed as described in A.7. pET21a-
Cint.egfp.Thr.6H.Nint, pET21a-Cint.egfpnoc.Thr.6H.Nint (C49G and C71G), and 
pET21a-Cint.egfpind.Thr.6H.Nint (C49G, V69P, Q70L, F72L)  The proteins were 
expressed and purified as described in 2.3.1 Protein Expression,  and 2.3.2 IMAC 
Purification.  To confirm accurate amino acid modifications, purified proteins were 
analyzed for fluorescence.  It was hypothesized the deletion of the amino acids in 
(C)eGFP-GG and (C)eGFP-PLCL would disrupt the beta-barrel chain of wild type 
eGFP and inhibit fluorescence.  After purifying the proteins, the resulting elution 
fractions would be analyzed for erroneous protein fractions at 15kDa indicating 
internal ligation.  The elution samples were analyzed using a reducing SDS-PAGE 
and MALDI-TOF analysis. 
D.2.  Experimental Data 
 
The elution fractions of the three proteins did not identify any erroneous proteins to 
the wild type (C)eGFP elution patterns.  The elution patterns for the three proteins all 
appeared relatively similar as observed in Figure 44.  The relative sensitivity of SDS-
PAGE, using Coomassie Brilliant Blue R-250 is 30ng [220], therefore if the internal 
ligation was inefficient, only erroneous proteins could be identified using MALDI-
TOF.   It can be concluded the inclusion of artificial ligation sequences does not 






Figure 44. 4-20% Tris-Glycine Gel of Induced Intein, IMAC Elution Samples.  
No induction of internal ligation from the artifical codon was observed in the protein 
gels.  The 4-20% gel can enhance observation of low molecular weight proteins.   














Appendix G.  Media and Buffer Formulations 
 
G.1. LMR Media (Minimal Media) Formulation 
 
Media formulation, modified from MTM media.[221] 
 
1000mL solution of 20x (50mL/L) Nitrogen Phosphate Stock (NPS): 50g NH4Cl, 
14.2g Na2SO4, 136g KH2PO4, 142g Na2HPO4 
1000mL solution of 50x Carbon Source Stock (CSS): 300g glycerol, 125g D-glucose 
 
100mL solution of 10,000x (0.1mL/L) Trace Metals Stock (TMS): 50mL of 0.1M 
FeCl2 in 0.01MHCl, 2mL of 1M CaCl2, 1mL of 1M MnCl2, 1mL of 1M ZnCl2, 1mL 
of 0.2M CoCl2, 2mL of 0.1M CuCl2, 1mL of- 0.2M NiCl2, 2mL of 0.1M Na2MoO4, 
2mL of 0.1M Na2SeO3, 2mL of 0.1M H3BO3 
 
100mL solution of 1000x (1mL/L) Vitamin Stock (VS): 4mL- 5mM vitamin B12 
(0.2 mM), 2 mL of 10 mM thiamine– HCL, 2mL- 10mM nicotinic acid (0.2 mM), 
2mL- 10mM pyridoxine-HCl (0.2 mM), 2mL -10mM p-aminobenzoic acid (0.2 mM), 
5mL- 100µM folic acid (5 µM), 5mL- 100µM riboflavin (5 µM) 
 
2L of LMR: 1.85L water, 2mL 1M MgSO4, 200µL TMS, 40mL CSS, 100mL NPS, 
2mL VS.  Adjust to pH6.8 if necessary. 
 
G.2  IMAC Column Buffers 
 
IMAC Load/Lyse Buffer: 50mM Tris-base, 500mM NaCl, 20mM Imidizol 
IMAC Wash Buffer: 50mM Tris-base, 500mM NaCl, 50mM Imidizol 
IMAC Elution Buffer: 50mM Tris-base, 500mM NaCl, 300mM Imidizol 
 
 
Appendix H. Evaluation of sodium azide on cell transduction effeciency 
 
The exact mechanism of cell transduction is not defined for peptide-protein, TAT-
fusion systems.  However, sodium azide has been shown to inhibit endocytosis of cell 
penetrating peptides [222].  In theory, sodium azide inhibits the energy-dependent 
endocytosis by oxidative phosphorylation within the cell membrane.  The inhibition 




endocytosis [223, 224].  In this experiment, sodium azide (10µm and 1µm) was added 
to the cell culture media during co-incubation of (C)eGFP or (C)TATeGFP with 
CHO-cells.  After incubation of 15 and 60-minutes, the extracellular fluorescence was 
quenched with trypan blue.  From Figure 45, at 10µm, sodium azide reduces the 
relative fluorescence of cells incubated without a fluorescent protein.  At 1µm, 
sodium azide does not have a significant effect on the transduction of GFP. 
 
Figure 45 - Sodium Azide does not inhibit endocytosis of intein-derived TAT-
peptide protein fusions.  At 10µm, sodium azide reduces the relative fluorescence of 
cells incubated without a fluorescent protein.  At 1µm, sodium azide does not have a 
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